1. Agarwal, S. L. and Bhargava, V., Effect of drugs on brain acetylcholine levels in rats, Indian J. Med. Res., 52: 1179-1182, 1964.

2. Alarcon-Segovia, D., Wakim, K. G., Worthington, J. W., and Ward, L. E., Clinical and experimental studies on the bydralazine syndrome and its relationship to systemic lupus crythematosus, Medicine, 46: 1-33, 1967.

3. Alvarez, W. C., Pseudo-ulcer, Gastroenterology, 14: 321-323, 1950.

4. Alvarez, W. C., “Why, that’s our Jimmy,” Mod. Med., 75-76, 1968.

5. Aring, C. D., Management of fits in adults, Ohio Med. J., 37: 225-230, 1941.

6. Aston, R. and Domino, E. F., Differential effects of phenobarbital, pentobarbital and diphenylhydantoin on motor cortical and reticular thresholds in the rhesus monkey, Psychopharmacologia, 2: 304-317, 1961.

7. Baer, P. N., Davis, R. K., and Merrit, A. D., Studies on Dilantin hyperplastic gingivitis: the role of magnesium, J. Dent. Res., 44: 1055, 1965.

8. Baldwin, R. W. and Kenny, T. J., Medical treatment of behavior disorders, Learning Disabilities, J. Hellmuth, Ed., 2: 313-327, Special Child Publications of The Seattle Seguin School, Inc., Seattle, 1966.

9. Baxi, S. M., Trigeminal neuralgia: treatment with diphenylhydantoin, Antiseptic, 58: 329-330, 1961.

10. Becker, R. and Balshiisernann, T., Treatment of facial pain, Deutsch Med. Wschr., 90: 2014-2020, 1965.

11. Putnam, T. J. and Merritt, H. H., Experimental determination of the anticonvulsant properties of some phenyl derivatives, Science, 85: 525-526, 1937.

12. Belton, N. R., Etheridge, J. E., Jr., and Millichap, J. G., Effects of convulsions and anticonvulsants on blood sugar in rabbits, Epilepsia, 6: 243-249,1965.

13. Bente, D., Schönhärl, E., and Krump-Erlangen, J., Electroencephalographic findings in stutterers and their application to medical therapy, Archiv für Ohren-, Nasen- und Kehlkopfheilkunde, 169: 513-519,1956.

14. Bergouignan, M., Fifteen years of therapeutic trials in essential trigeminal neuralgia: the place of diphenylhydantoin and its derivatives, Rev. Neural. (Paris), 98: 414-416, 1958.

15. Bergouignan, M., Successful cures of essential facial neuralgias by sodium diphenylhydantoinate, Rev. Laryng. (Bordeaux), 63: 34-41, 1942.

16. Bergouignan, M. and d’Aulnay, N., Effects of sodium diphenylhydantoin in essential trigeminal neuralgia, Rev. Otoneuroopthal. (Paris), 23: 427-431, 1951.

17. Bernsohn, L., Possley, L., and Custod, J. T., Alterations in brain adenine nucleotides and creatinine phosphate in vivo after the administration of chlorpromazine, JB-516, Dilantin and RO 5-0650 (Librium), Pharmacologist, 2: 67, 1960.

18. Bernstein, H., Gold, H., Lang, T. W., Pappelbaum, S., Bazika, V., and Corday, E., Sodium diphenylhydantoin in the treatment of recurrent cardiac arrhythmias, JAMA, 191: 695-697, 1965.

19. Bigger,j. T.,Jr., Bassett, A. L., and Hoffman, B. F., Electrophysiological effects of diphenylhydantoin on canine Purkinje fibers, Circ. Res., 22: 221-236, 1968.

20. Bigger, J. T., Jr., Harris, P. D., and Weinberg, D. I., Effects of diphenylhydantoin on cardiac conduction and repolarization, Amer. J. Cardiol., 19: 119-120, 1967.

21. Bigger, 1. T., Jr., Schmidt, D. H., and Kutt, H., The relationship between the antiarrhythmic effect and the plasma level of diphenylhydantoin sodium (Dilantin), Bull. N.Y. Acad. Med., 42:1039,1966.

22. Bigger, J. T., Jr., Strauss, H. C., and Hoffmann, B. F., Effects of diphenylhydantoin on atrioventricular conduction, Fed. Proc., 27: 406, 1968.

23. Blatrnan, S. and Metcalf, D. R., Abnormal electroencephalograms in asthmatic children, Amer. J. Dis, Child., 102: 531, 1961.

24. Blaw, M. E. and Torres, F., Treatment of pseudoretardation associated with epilepsy, Mod. Treatm., 4: 799-816, 1967.

25. Bodkin, L. G., Oral therapy for pruritus ani, Amer. J. Dig. Dis., 12: 255-257, 1945.

26. Bodkin, L. G., Pruritus ani: a review of oral therapy, Amer. Dig. Dis., 14: 109-113, 1947.

27. Boelhouwer, C., Henry, C. E., and Glueck, B. C., Positive spiking: a double blind control study on its significance in behavior disorders, both diagnostically and therapeutically, Amer. J. Psychiat., 125: 473-481, 1968.

28. Bogoch, S., Diphenylhydantoin: therapeutic uses and mechanisms of action, Dreyfus Medical Foundation, 1968.

29. Booker, H. E., Matthews, C. G., and Slaby, A., Effects of diphenylhydantoin on physiological and psychological measures in normal adults, Neurology, 17: 949-951, 1967.

30. Bose, B. C., Saifi, A. Q., and, Sharma, S. K., Studies on anticonvulsant and antifibrillatory drugs, Arch. Int. Pharmacodyn., 146: 106-113, 1963.

31. Braham, J. and Saia, A., Phenytoin in the treatment of trigeminal and other neuralgias, Lancet, 2: 892-893, 1960.

32. Braverman, 1. M., and Levin, J., Dilantin-induced serum sickness: case report and inquiry into its mechanism, Amer. J. Med., 35: 418-422, 1963.

33. Bray, P. F., Diphenylhydantoin (Ditantin) after 20 years: a review with re-emphasis by treatment of 84 patients, Pediatrics, 23: 151-161, 1959.

34. Brennan, R. W., Dehejia, M., Kutt, H., and McDowell, F., Diphenylhydantoin intoxication attendant to slow inactivation of isoniazid, Neurology, 18: 183, 1968.

35. Brill, N. Q., and Walker, E. F., Psychopathic behavior with latent epilepsy, J. Nerv. Ment. Dis., 101: 545-549, 1945.

36. Brittingbam, T. E., Lutcher, C. L., and Murphy, D. L., Reversible erythroid aplasia induced by diphenylhydantoin, Arch. Intern. Med., 113: 764-768, 1964.

37. Broddle, W. D. and Nelson, S. R., The effect of diphenylhydantoin on energy reserve levels in brain, Fed. Proc., 27: 751, 1968.

38. Brown, W. T. and Solomon, C. I., Delinquency and the electroencephalograph, Amer. J. Psychiat., 98: 499-503, 1942.

39. Buchthal, F. and Svensmark, O., Aspects of the pharmacology of Phenytoin (Dilantin) and phenobarbital relevant to their dosage in the treatment of epilepsy, Epilepsia, 1: 373-384, 1959-1960.

40. Burke, E. C. and Peters, G. A., Migraine in childhood: a preliminary report, A.M.A. J. Dis. Child., 92: 330-336, 1956.

41. Byrne, J. E. and Dresel, P. E., A model for evaluating drugs which prolong post-countershock periods of normal sinus rhythm (NSR), Pharmacologist, 10: 220, 1968.

42. Cameron, A. J., Baron, J. H., and Priestley, B. L., Erythema multiforme, drugs, and ulcerative colitis, Brit. Med. J., 2: 1174-1178, 1966.

43. Campbell, E. W., Jr., and Young, J. D., Jr., Enuresis and its relationship to electroencephalographic disturbances, J. Urol., 96: 947-949, 1966.

44. Cantu, R. C. and Schwab, R. S., Ceruloplasmin rise and PBI fall in serum due to diphenylhydantoin, Arch. Neurol., 15: 393-396, 1966.

45. Cantu, R. C., Schwab, R. S., and Timberlake, W. H., Comparison of blood levels with oral and intramuscular diphenylhydantoin, Neurology, 18: 782-784, 1968.

46. Case, W. G., Rickels, K., and Bazilian, S., Diphenylhydantoin in neurotic anxiety, Amer. J.,Psychiat., 126: 254-255, 1969.

47. Caspers, H. and WehmeyLr, H., The action of diphenylhydantoin on the seizure threshold of the brain, Z. Ges. Exp. Med., 129: 77-86, 1957.

48. Caveness, W., Adams, R. D., Pope, A., and Wegner, W. R., The role of the dorsal root ganglia in the production of the lancinating pains of central nervous system syphilis, Trans. Amer. Neurol. Assn., 60-64, 1949.

49. Chaiken, B. H., Goldberg, B. I., and Segal, J. P., Dilantin sensitivity: report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis, New Eng. J. Med., 242: 897-898, 1950.

50. Chang, T. and Glazko, A. J., Quantitative assay of 5,5’-diphenylhydantoin (Dilantin) and 5-(4-hydroxyphenyl)-5’-phenylhydantoin by gas-liquid chromatography, Clin. Res., 16: 339, 1968.

51. Chao, D., Sexton, J. A., and Davis, S. D., Convulsive equivalent syndrome of childhood, J. Pediat, 64: 499-508, 1964.

52. Chenoweth, M. B., Clinical uses of metal binding drugs, Chn.,Pharm”ol. Ther., 9: 365-387, 1968.

53. Childress, R. H., Higgs, L. M., Boyd, D. L., and Williams, J. F.,Jr., Effect of diphenylhydantoin on left ventricular function in patients with heart disease, Circulation, 33-34: 73, 1966.

54. Chinitz, A., Seelinger, D. F., and Greenhouse, A. H., Anticonvulsant therapy in trigeminal neuralgia, Amer. J. Med. Sci., 252: 62-67, 1966.

55. Christensen, K., On the preparation and stability of Phenytoin solutions for injection, Dansk Tidsskr. Farm., 34: 97-109, 1960.

56. Chung, A. C., The influence of diphenyihydantoin (Dilantin) on the development of atherosclerosis in rabbits, J. Atheroscler. Res., 7: 373-379, 1967.

57. Chung, A. C., Duren, B. Y., and Houck, J. C., Effect of diphenylhydantoin administration upon concentration of liver and aortic lipids, Proc. Soc. Exp. Biol. Med., 110: 788-789, 1962.

58. Cohen, H. B., Duncan, R. F., 11, and Dement, W. C., The effect of diphenylhydantoin and sleep in the cat, Electroenceph. Clin. Neurophysiol., 24: 401-408, 1968.

59. Cohen, H. D. and Barondes, S. H., Puromycin effect on memory may be due to occult seizures, Science, 157: 333-334, 1967.

60. Cole, J. O. and Davis, J. M., Brief report of papers on diphenylhydantoin in plenary session, American College of Neuropsychopharmacology, fifth annual meeting, Psychopharm. Bull. 4: 28-31, 1967.

61. Conn, R. D., Diphenylhydantoin sodium in cardiac arrhythmias, New Eng. J. Med., 272: 277-282, 1965.

62. Conn., R. D., New drugs for old hearts: newer antiarrhythmic and diuretic agents, Postgrad. Med. 42: 71-79, 1967.

63. Corday, E., Lang, T. W., Bazika, V., and Pappelbaurn, S., Antiarrhythmic acts directly on myocardium, JAMA, 193: 28, 1965.

64. Cox, A. R., Pitt, W., Brown, T. C. K., and Molaro, A., Antiarrhythmic action of diphenylhydantoin (Dilantin) studied in isolated cardiac tissue, Canad. Med. Assn. J., 94: 661, 1966.

65. Crawford, S. E. and Jones. C. K., Fatal liver necrosis and diphenylhydantoin sensitivity, Pediatrics, 30: 595-600, 1962.

66. Crue, B. L., Jr., Alvarez-Carregal, E., and Todd, E. M., Neuralgia: consideration of central mechanisms, Bull. Los Angeles Neurol. Soc., 29: 107-132, 1964.

67. Crue, B. L., Jr., Todd, E. M., and Duemler, L. P., Pain as sensory epilepsy, Bull. Los Angeles Neurol. Soc., 32: 53, 1967.

68. Crue, B. L., Jr., Todd, E. M., and Loew, A. G., Clinical use of mephenesin carbamate (Tolserarn) in trigeminal neuralgia, Bull. Los Angeles Neural. Soc., 30; 212-215, 1965.

69. Cucinell, S. A., Factors affecting drug metabolism, Bull. N.Y. Acad. Med., 42: 324, 1966.

70. Popek, K., Czechs make anticonvulsants a must for coma victims, Med. World News, 33, March 8, 1968.

71. Dab], J. R., Diphenylhydantoin toxic psychosis with associated hyperglycemia, Calif. Med., 107: 345-347, 1967.

72. Dam, M., Organic changes in Phenytoin intoxicated pigs, Acta Neurol. Scand., 42: 491-494, 1966.

73. Dam, M. and Olesen, V., Intramuscular administration of Phenytoin, Neurology, 16: 288-292, 1966.

74. Dayton, P. G., Cucinell, S. A., Weiss, M., and Perel, J. M., Dose dependence of drug plasma level decline in dogs, J. Pharm. Exp. Ther., 158: 305-316,1967.

75. de la Vega, P., Clinical results of the treatment of Sydenham’s chorea with sodium diphenylhydantoin, Rev. Clin. Esp. 24: 113-115, 1947.

76. Dill, R. E., Discrepancy of adrenal responses in diphenylhydantoin treated rats, Arch. Int. Pharmacodyn., 160: 363-372, 1966.

77. Dill, W. A., Kazenko, A., Wolf, L. M., and Glazko, A. J., Studies on 5,5’-diphenylhydantoin (Dilantin) in animals and man, J. Pharm. Exp. Ther., 118: 270-279, 1956.

78. Dimsdale, H., Migraine, Practitioner, 198: 490-494, 1967.

79. Dixon, R. L., The interaction between various drugs and methotrexate, Toxic. Appl. Pharmacol., 12: 308, 1968.

80. Dorph, M., Coronary care units and the aggressive management of acute myocardial infarction, Delaware Med. J. 44-48, February, 1968.

81. Dorsey, J. F., Haystip, G. W., and Anderson, K., Tic douloureux: treatment with diphenylhydantoin, Clin. Med., 6: 13951397, 1959.

82. Dreifus, L. S., Rabbino, M. D., and Watanabe, V., Newer agents in the treatment of cardiac arrythmias, Med. Clin. N. Ame,r., 48: 371-387, 1964.

83. Druskin, M. S., Anticonvulsants and anemia, Clin. Med., 71: 1911-1916, 1964.

84. I)ruskin, M. S., Wailen, M. H., and Bonagura, L., Anticonvulsant associated megaloblastic anemia: response to 25 microgm. of folic acid administered by mouth daily, New Eng. J. Med., 267: 483-485, 1962.

85. Dubois, E. L., Toxic hepatic necrosis associated with taking Dilantin, Tridione and phenobarbital, Amer. J. Clin. Path., 20: 153-158, 1950.

86. Duma, R. J., Hendry, C. N., and Donahoo, J. S., Hypersensitivity to diphenylhydantoin (Dilantin): a case report with toxic hepatitis, Southern Med. J., 59: 168-170, 1966.

87. Dutton, P., Phenytoin toxicity with associated meningeal reactions. J. Ment. Sci., 104: 1165-1166, 1958.

88. Eissner, H., Diphenylhydantoin exanthema in the form of infectious mononucleosis, Arch. Toxik., 18: 282-295,1960.

89. Endröczi, E. and Fekete, T., Amino acid composition of the Ammon’s horn and the effect of anticonvulsant drugs, Acta Physiol. Acad. Sci. Hung., 32: 389-398, 1967.

90. Esplin, D. W., Effects of diphenylhydantoin on synaptic transmission in cat spinal cord and stellate ganglion, J. Pharm. Exp. Ther., 120: 301-323, 1957.

91. Fabrykant, M., Further studies on electrocerebral dysfunction and the use of anticonvulsants in labile diabetes, Ann. Intern. Med., 38: 814-823, 1953.

92. Fabrykant, M. and Pacella, B. L., Labile diabetes: electroencephalographic status and effect of anticonvulsive therapy, Ann. Intern. Med., 29: 860-877, 1948.

93. Ferngren, H. and Paalzow, L., Studies on electrically induced seizures and their antagonism by anticonvulsants during neonatal development in the mouse, Acia Pharinaeol. Toxicol., 25: 60, 1967.

94. Festoff, B. W. and Appel, S. H., Effect of diphenylhydantoin on synaptosome sodium-potassium-ATPase, J. Clin. Invest., 47: 2752-2758, 1968.

95. Fetterman, J. L. and Shallenberger, W. D., Further studies in Dilantin sodium therapy of epilepsy, Dis. Nerv. System, 2: 383-389, 1941.

96. Fichman, M. P. and Bethune, J. E., The role of adrenocorticoids in the inappropriate antidiuretic hormone syndrome, Ann. Intern. Med., 68: 806-820, 1968.

97. Fichman, M. P., Kleeman, C. R. and Bethune, Inhibition of antidiuretic hormone secretion by diphenylhydantoin, Arch. Neurol., 22: 45-53, 1970.

98. Finch, E. and Lorber, J., Methaemoglobinaemia in the newborn: probably due to Phenytoin excreted in human milk, Obstet. Gynaec. Brit. Emp., 61: 833-834, 1954.

99. Fink, G. B. and Swinyard, E. A., Comparison of anticonvulsant and psychopharmacologic drugs, J. Pharm. Sci., 51: 548-551, 1962.

100. Finkelman, 1. and Arieff, A. J., Untoward effects of Phenytoin sodium in epilepsy, JAMA, 118: 1209-1212, 1942.

101. Firemark, H., Barlow, C. F., and Roth, L. J., The entry, accumulation and binding of diphenylhydantoin-2-C14 in brain: studies on adult, immature and hypercapnic cats, Int. J. Neuropharmacol, 2: 25-38, 1963.

102. Fishbeck, R. and Zucker, G., Phenytoin (5,5-diphenylhydantoin) hypersensitivity presenting a clinical picture of scarlatiniform erythroderma, Deutsch. Gesundh., 21; 1273-1277, 1966.

103. Floyd, F. W., The toxic effects of diphenylhydantoin: a report of 23 cases, Clin. Proc. Child Hosp., D. C., 17: 195-201, 1961.

104. Forshaw, J. W. B., Megaloblastic anemia associated with anticonvulsant therapy, Postgrad. Med. J. (London), 33: 242-243, 1957.

105. Fox, V., Treatment of the non-neurologic complications of alcoholism, Mod. Treatm., 3: 502-508, 1966.

106. Frankel, S. I,. Dilantin sodium in the treatment of epilepsy, JAMA,114: 1320-1321, 1940.

107. Frantzen, E., Hansen, J. M., Hansen, O. E., and Kristensen, M., Phenytoin (Dilantin) intoxication, Acta Neurol Scand., 43: 440-446, 1967.

108. Freed, L. F., The psychopath: a social challenge, Med. Proc., 13: 408-414, 1967.

109. Frey, H. H., Kampmann, E., and Nielsen, C. K., Study on combined treatment with phenobarbital and diphenylhydantoin, Arta Pharmacol. Toxic., 26: 284-292, 1968.

110. Freyhan, F. A., Effectiveness of diphenylhydantoin in management of nonepileptic psychomotor excitement states, Arch. Neurol. Psychiat., 53: 370-374, 1945.

111. Friedman, A. P., The migraine syndrome, Bull. N.Y. Acad. Med., 44: 45-62, 1968.

112. Friedman, A. P. and Merritt, H. H., Treatment of headache, JAMA, 163: 1111-1117, 1957.

113. Gabka, J., On the therapy of idiopathic and symptomatic head and facial pains, Med. Mschr., 17: 430-443, 1963.

114. Galindo, A. M. and Ginabreda, J. M. S., Treatment of chorea minor with diphenylhydantoin sodium, Ann. Med. (Barcelona), 34: 165-168, 1947.

115. Garouette, J. V., A suggested mechanism of action for the anticonvulsant properties of diphenylhydantoin, Tulane U. Med. Fac. Bull., 24: 319-328, 1965.

116. Gatenby, P. B. B., Anticonvulsants as a factor in megaloblastic anemia in pregnancy, Lancet, 2: 1004-1005, 1960.

117. Gautray, J. P. and Natter, S., The significance of EEG and of neuro-sedative therapies in the gynecology clinic, Ann. Endocr., 22: 173-185, 1961.

118. Gayet-Hallion, T. and Bertrand, I., Favorable action of diphenylhydantoin on the resistance of rats to drowning, Compt. Rend. Soc. Biol., 153: 757-759,1959.

119. Gellerman, G. L. and Martinez, C., Fatal ventricular fibrillation following intravenous sodium diphenylhydantoin therapy, JAMA, 200: 337-338, 1967.

120. Gellman, V., A case of diphenylhydantoin (Dilantin) intoxication, Manitoba Med. Rev., 46: 388-390, 1966.

121. Gershbein, L. L., Effect of drugs and catecholamines on rat diaphragm carbohydrate metabolism, J. Pharm. Sci., 55: 846-848,1966.

122. Gilbert, J. C., Ortiz, W. R., and Millichap, J. G., The effects of anticonvulsant drugs on the permeability of brain cells to D-xylose, J. Neurochem., 13: 247-255, 1966.

123. Golbert, T. M., Sanz, C. J., Rose, H. D., and Leitschuh, T. H., Comparative evaluation of treatments of alcohol withdrawal syndromes, JAMA, 201: 99-102, 1967.

124. Goldschlager, A. W. and Karliner, J. S., Ventricular standstill after intravenous diphenylhydantoin, Amer. Heart J., 74: 410-412, 1967.

125. Goldstein, N., Leider, M., and Baer, R. L., Drug eruptions from anticonvulsant drugs, Arch. Derm., 87: 612-617, 1963.

126. Gordon, P., Diphenylhydantoin and procainamide normalization of suboptimal learning behavior, Recent Advances Biol. Psychiat., 10: 121-133, 1968.

127. Goodwin, F. B., Oral therapy in anogenital pruritus, J. Nat. Proct. Assn., 18: 84-87, 1946.

128. Granick, S., The induction in vitro of the synthesis of 8-aminolevulinic acid synthetase in chemical porphyria: a response to certain drugs, sex hormones, and foreign chemicals, J. Biol. Chem., 241: 1359-1375, 1966.

129. Green, J. B., Dilantin in the treatment of lightning pains, Neurology, 11: 257-258, 1961.

130. Green, J. B., Electroencephalographic findings in a case of acute reaction to Dilantin, Electroenceph. Clin. Neurophysiol., 20: 201-202, 1966.

131. Gretter, T. E., Danner, P. K., Nibbelink, D. W., Green, D., and Sahs, A. L., The effect of diphenylhydantoin (Dilantin) on acute intermittent porphyria, Trans. Amer. Neurol. Assn., 88: 176-178,1963.

132. Grissom, J. H., Sy, B. G., Duffy, J. P., and Dunea, G., Dangerous consequence from use of Phenytoin in atrial flutter, Brit. Med. J., 4: 34, 1967.

133. Gropper, A. L., Diphenylhydantoin sensitivity: report of fatal case with hepatitis and exfoliative dermatitis, New Eng. J. Med., 254: 522-523,1956.

134. Grosz, H. J., Dilantin intoxication-with a report of one case, Amer. Pract. Dig. Treatm., 7: 1633-1636, 1956.

135. Gupta, R. C. and Kofoed, J., Toxicological statistics for barbiturates, other sedatives, and tranquilizers in Ontario: a 10 year survey, Canad. Med. Assn. J., 94: 863-865, 1966.

136. Gydell, K., Megaloblastic anemia in patients treated with diphenylhydantoin and primidone, Acta Haemat., 17: 1-15, 1957.

137. Hamfelt, A., Killander, A., Malers, E., and de Verdier, C., Megaloblastic anemia associated with anticonvulsant drugs, Acta Med. Scand., 177: 549-555, 1965.

138. Hansen, J. M., Kristensen, M., Skovsted, L., and Christensen, L. K., Dicoumarol-induced diphenylhydantoin intoxication, Lancet, 2: 265-266, 1966.

139. Hansen, H. A., Nordqvist, P., and Sourander, P., Megaloblastic anemia and neurologic disturbances combined with folic acid deficiency: observations on an epileptic patient treated with anticonvulsants, Acta Med. Scand., 176: 243-251, 1964.

140. Harinasuta, U. and Zimmerman, H. J., Diphenylhydantoin sodium hepatitis, JAMA, 203: 1015-1018, 1968.

141. Harris, A. S. and Kokernot, R. H., Effects of diphenylhydantoin sodium (Dilantin sodium) and phenobarbital sodium upon ectopic ventricular tachycardia in acute myocardial infarction, Amer. J. Physiol, 163: 505-516, 1950.

142. Harris, J. and Ritchie, K., Anticonvulsant effects on copper uptake by neural tissue, Fed. Proc., 25: 2091, 1966.

143. Harris, P. D., Bigger, J. T., J r., Weinberg, D., and Malm, R., Use of diphenylhydantoin in ventricular arrhythmias following open heart surgery, Surg. Forum, 17: 185-188, 1966.

144. Hartmann, J. F., High sodium content of cortical astrocytes: electron microscope evidence, Arch. Neurol, 15: 633-642, 1966.

145. Hatzmann, I., Neuhold, R., and von Rittner, W., Exfoliative dermatitis after hydantoin therapy, Ann. Pediat. (Basel), 179: 305-316,1952.

146. Hausser, E., Bergoz, R. and Croci, D., Megaloblastic anemia provoked by antiepileptic medications, Nouv. Rev. Franc. Hemat., 4: 221-232, 1964.

147. Hawkins, C. F. and Meynell, M. J., Macrocytosis and macrocytic anemia caused by anticonvulsant drugs, Quart. J. Med., 27: 45-63, 1958.

148. Hawkins, C. F. and Meynell, M. J., Megaloblastic anemia due to Phenytoin sodium, Lancet, 2: 737-738, 1954.

149. Helfant, R. H., Scherlag, B. J., and Damato, A. N., The comparative electrophysiological effects of diphenylhydantoin and procaine amide in the digitalis intoxicated and nondigitalized heart, Clin. Res., 15: 206, 1967.

150. Helfant, R. H., Scherlag, B. J., and Damato, A. N., The use of diphenylhydantoin in ventricular arrhythmias unresponsive to procaine amide: a dissociation of procaine amide’s actions on automaticity and conduction, Circulation, 36: 139, 1967.

151. Helfant, R. H., Scherlag, B. J., and Damato, A. N., Diphenylhydantoin prevention of arrhythmias in the digitalis-sensitized dog after direct-current cardioversion, Circulation, 37: 424-428, 1968.

152. Helfant, R. H., Scherlag, B. J., and Damato, A. N., Diphenylhydantoin toxicity, JAMA, 201: 894, 1967,

153. Helfant, R. H., Scherlag, B. J., and Damato, A. N., Electrophysiological effects of direct current countershock before and after ouabain sensitization and after diphenylhydantoin desensitization in the dog, Circ. Res., 22: 615-623, 1968.

154. Helfant, R. H., Scherlag, B. J., and Damato, A. N., The electrophysiological properties of diphenylhydantoin sodium as compared to procaine amide in the normal and digitalis intoxicated heart, Circulation, 36: 108-118, 1967.

155. Helfant, R. H., Scherlag, B. J., and Damato, A. N., Protection from digitalis toxicity with the prophylactic use of diphenylhydantoin sodium: an arrhythmic-inotropic dissociation, Circulation, 36: 119-124, 1967.

156. Helfant, R. H., Scherlag, B. J., and Damato, A. N., Use of diphenylhydantoin sodium to dissociate the effects of procaine amide on automaticity and conduction in the normal and arrhythmic heart, Amer. J. Cardiol., 20: 820-825, 1967.

157. Helfant, R. H., Ricciutti, M. A., Scherlag, B. J., and Damato, A. N., Effect of diphenylhydantoin sodium (Dilantin) on myocardial A-V potassium difference, Amer. J. Physiol., 214: 880-884, 1968.

158. Helfant, R. H., Lau, S. H., Cohen, S. I., and Damato, A. N., Effects of diphenylhydantoin on atrioventricular conduction in man, Circulation, 36: 686-691, 1967.

159. Herman, C. J. and Bignall, K. E., Effects of diphenylhydantoin on spontaneous and evoked activity in the cat under chloralose anesthesia, Electroenceph. Clin. Neurophysiol., 23: 351-359, 1967.

160. de la Herran, J., Martinez-Lage, J. M., and Molina, P., Treatment of trigeminal neuralgia with diphenylhydantoin and disulphur of pyridoxine, Medicina Clinica, 38: 375-378, 1962.

161. Hirschmann, J., On the interval treatment of migraine, Ther. Umsch., 21; 48-51, 1964.

162. Hoaken, P. C. S., and Kane, F. J., Jr., Unusual brain syndrome seen with diphenylhydantoin and pentobarbital, Amer. Psychiat., 120: 282-283, 1963.

163. Hockman, C. H., Mauck, H. P., Jr., and Chu, N., ECG changes resulting from cerebral stimulation. 111. Action of diphenylhydantoin on arrhythmias, Amer. Heart J., 74: 256-260, 1967.

164. Hoff, E. C. and Yahn, C., The effect of sodium 5,5-diphenylhydantoinate (Dilantin sodium) upon the tolerance of rats and mice to decompression. Amer. J. Physiol, 141: 7-16, 1944.

165. Hofmann, W. W., Cerebellar lesions after parenteral Dilantin administration, Neurology, 8: 210-214, 1958.

166. Holecková, R., Some experiences in treatment of cardiac arrhythmias using diphenylhydantoin, Vnitmi. Lek., 13: 1195-1196, 1967.

167. Holland, P. and Mauer, A. M., Diphenylhydantoin induced hypersensitivity reaction, J. Pediat., 66: 322-332, 1965.

168. Hopf, H. C., On the alteration of transmission function of peripheral motor nerve fibers through diphenylhydantoin, Deutsch Z. Nervenheilk, 193: 41-56, 1968.

169. Horsfield, G. 1. and Chalmers, J. N. M., Megaloblastic anemia associated with anticonvulsant therapy, Practitioner, 19 1: 316-321, 1963.

170. Horwitz, S. J., Klipstein, F. A., and Lovelace, R. E., Relation of abnormal folate metabolism to neuropathy developing during anticonvulsant drug therapy, Lancet, 1: 563-565, 1968.

171. Houck, J. C. and Patel, Y. M., Proposed mode of action of corticosteroids on the connective tissue, Nature, 206: 158-160, 1965.

172. Houck, J. C., Jacob, R. A., and Maengwyn-Davies, G. D., The effect of sodium Dilantin administration upon the chemistry of the skin, J. Clin. Invest., 39: 1758-1762, 1960.

173. Huisman, J. W., The estimation of some important anticonvulsant drugs in serum, Clin. Chim. Acta, 13: 323-328, 1966.

174. Husby, J., Delayed toxicity and serum concentrations of Phenytoin, Danish Med., Bull., 10: 236-239, 1963.

175. Iannone, A., Baker, A. B., and Morrell, F., Dilantin in the treatment of trigeminal neuralgia, Neurology, 8: 126-128, 1958.

176. Isaacs, H., A syndrome of continuous muscle-fibre activity. J. Neurol. Neuro-surg. Psychiat., 24: 319-325, 1961.

177. Isaacs, H., Quantal squander, S. A. J. Lab. Clin. Med., 10: 93-95, 1964.

178. Itil, T. M., Rizzo, A. E., and Shapiro, D. M., Study of behavior and EEG correlation during treatment of disturbed children, Dis. Nerv. Syst., 28: 731-736, 1967.

179. Jensen, B. N. and Grynderup, V., Studies on the metabolism of Phenytoin, Epilepsia, 7: 238-245, 1966.

180. Jensen, H. P., The treatment of trigeminal neuralgia with diphenylhydantoin, Arztl. Wochschr., 9: 105-108, 1954.

181. Jonas, A. D., The diagnostic and therapeutic use of diphenylhydantoin in the subictal state and non-epileptic dysphoria, Int. J. Neuropsychiat., 3: S21 -S29, 1967.

182. Jurna, I., Depression by antiparkinson drugs of reserpine rigidity, Naunyn-Schmiedeberg Arch. Pharm., 260: 80-88, 1968.

183. Jurna, I. and Regélhy, B., The antagonism between reserpine and some antiparkinson drugs in electroseizure, Naunyn-Schmiedeberg Arch. Pharm., 259: 442-459, 1968.

184. Kabat, H., Drug therapy of cerebellar ataxia and disorders of the basal ganglia, based on cerebellar-striatal antagonism, Ann. Intern. Med., 50: 1438-1448, 1959.

185. Kabat, H. and McLeod, M., Neuromuscular dysfunction and treatment in athetosis, Conn. Med., 23: 710-714, 1959.

186. Kalinowsky, L. B. and Putnam, T. J., Attempts at treatment of schizophrenia and other nonepileptic psychoses with Dilantin, Arch. Neurol. Psychiat., 49: 414-420, 1943.

187. Karliner, J. S., Intravenous diphenylhydantoin sodium (Dilantin) in cardiac arrhythmias, Dis. Chest, 51: 256-269, 1967.

188. Kelin, E. E., Further studies of an epilepsy drug, Dental Prog., 3: 271-273, 1963.

189. Kelin, E. E. and Gorlin, R. J., Healing qualities of an epilepsy drug, Dental Prog., 1: 126-129, 196 1.

190. Kemp, J. W. and Swinyard, E. A., Diphenylhydantoin inhibition of hexobarbital metabolism by liver microsomes in mice and rats, Fed. Proc., 27: 350, 1968.

191. Kertesz, A., Paroxysmal kinesigenic choreoathetosis: an entity within the paroxysmal choreoathetosis syndrome, Neurology, 17: 680-690, 1967.

192. Khan, M. T. and McEwen, H. D., Effect of diphenylhydantoins on rat uterus in vitro, Proc. Can. Fed. Biol. Soc., 10: 161, 1967.

193. Kidd, P. and Mollin, D. L., Megaloblastic anemia and vitamin-BI2 deficiency after anticonvulsant therapy: report of two cases, Brit. Med. J., 2: 974-976, 195 7.

194. Kiørboe, E., Phenytoin intoxication during treatment with antabuse (Disulfiram), Epilepsia, 7: 246-249, 1966.

195. Kiørboe, E. and Plum, C. M., Megaloblastic anemia developing during treatment of epilepsy, Acia Med. Scand., 179: suppl. 445, 349-357, 1966.

196. Klein, D. F. and Greenberg, I. M., Behavioral effects of diphenylhydantoin in severe psychiatric disorders, Amer. J. Psychiat., 124: 847-849, 1967.

197. Klipstein, F. A., Subnormal serum folate and macrocytosis associated with anticonvulsant drug therapy, Blood, 23: 68-86, 1964.

198. Krieger, D. T., Effect of diphenylhydantoin on pituitaryadrenal interrelations, J. Clin. Endocrinol. Metab., 22: 490-493, 1962.

199. Krieger, D. T. and Krieger, H. P., The effect of short-term administration of CNS-acting drugs on the circadian variation of the plasma 17-OHCS in normal subjects, Neuroendocrinology, 2: 232-246, 1967.

200. Kristensen, M., Hansen, J. M., Hansen, O. E., and Lund, V., Sources of error in the determination of Phenytoin (Dilantin) by Svensmark and Kristensen’s method, Acta Neuvol. Scand., 43: 447-450, 1967.

201. Kubanek, J. L. and Rowell, R. C., The use of Dilantin in the treatment of psychotic patients unresponsive to other treatment, Dis. Nerv. Syst., 7: 1-4, 1946.

202. Kugelberg, E. and Lindblom, U., The mechanism of the pain in trigeminal neuralgia. J. Neurol. Neurosurg. Psychiat., 22: 36-43, 1959.

203. Kurtzke, J. F., Leukopenia with diphenylhydantoin, Nerv. Ment. Dis., 132: 339-343, 1961.

204. Kutt, H., Intravenous use of diphenylhydantoin sodium, JAMA, 201: 210,1967.

205. Kutt, H., Haynes, J., and McDowell, F., The effect of phenobarbital upon diphenyihydantoin metabolism in man, Neurology, 15: 274-275, 1965.

206. Kutt, H., Louis, S., and McDowell, F., Intravenous diphenylhydantoin in experimental seizures: 1. Correlation of dose, blood, and tissue level in cats, Arch. Neurol., 18: 465-471, 1968.

207. Kutt, H. and McDowell, F., Management of epilepsy with diphenylhydantoin sodium: dosage regulation for problem patients, JAMA, 203: 969-972, 1968.

208. Kutt H., Winters, W., and McDowell, F., Depression of parahydroxylation of diphenylhydantoin by antituberculosis chemotherapy, Neurology, 16: 594-602, 1966.

209. Kutt, H., Winters, W., and McDowell, F., Determination of diphenylhydantoin and phenobarbital metabolites, Fed. Proc., 23:2346,1964.

210. Kutt, H., Wolk, M., Scherman, R., and McDowell, F., Insufficient parahydroxylation as cause of Dilantin toxicity, Neurology, 13: 356, 1963.

211. Kutt, H., Wolk, M., Scherman, R., and McDowell, F., Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity, Neurology, 14: 542-548, 1964.

212. Lach, J.L.,Bhansali, K.,and Blaug, S.M.,The chromatographic separation and determination of diphenylhydantoin and phenobarbital, J. Amer. Pharm. Assn., 47: 48-49, 1958.

213. Laird, R. D. and Fonner, R. L., The protective effect of sodium diphenylhydantoin in the hyperacute radiation syndrome, U.S. Army Med. Res. Lab., Fort Knox, Kentucky, Report No. 262, 1957.

214. Lamberts, A. E., Tic douloureux, J. Mich. State Med. Soc., 58: 95-96, 1959.

215. Lang, T. W., Bernstein, H., Barbieri, F. F., Gold, H. and Corday, E., Digitalis toxicity: treatment with diphenylhydantoin, Arch. Intern. Med., 116: 573-580, 1965.

216. Laubscher, F. A., Fatal diphenylhydantoin poisoning: a case report, JAMA, 198; 1120-1121, 1966.

217. Lauriault, C. D. and Jim, R. T. S., Diphenylhydantoin toxicity; lymphadenopathy and low platelet count, Pediatrics, 37: 341-342, 1966.

218. Lefkowitz, M. M., Effects of diphenylhydantoin on disruptive behavior: study of male delinquents, Arch. Gen. Psychiat., 20: 643-651, 1969.

219. Lee, W. Y., Grummer, H. A., Bronsky, D., and Waldstein, S. S., Acute water loading as a diagnostic test for the inappropriate ADH syndromes, J. Lab. Clin. Med., 58: 937, 1961.

220. Lees, F., Radioactive vitamin B12 absorption in the megaloblastic anemia caused by anticonvulsant drugs, Quart. J. Med., 30: 231-248, 1961.

221. Leonard, W. A., Jr., The use of diphenylhydantoin (Dilantin) sodium in the treatment of ventricular tachycardia, A.M.A. Arch. Intern. Med., 101: 714-717, 1958.

222. Levitt, J. M. and Bionstein, M., Toxic amblyopia resulting from sodium diphenyl hydantoinate, New York J. Med., 40: 1538-1539, 1940.

223. Lieberson, A. D., Schumacher, R. R., Childress, R. H., Boyd, D. L., and Williams, J. F., Jr., Effect of diphenylhydantoin on left ventricular function in patients with heart disease, Circulation, 36: 692-699, 1967.

224. Lindblom, U., Diphenylhydantoin for trigeminal neuralgia, Svensk Lakartidn, 58: 3186-3191, 1961.

225. Lindsley, D. B. and Henry, C. E., The effect of drugs on behavior and the electroencephalograms of children with behavior disorders, Psychosom. Med., 4: 140-149, 1942.

226. Livingston, S., Petersen, D., and Boks, L. L., Hypertrichosis occurring in association with Dilantin therapy, J. Pediat., 47: 351-352, 1955.

227. Livingston, S. and Whitehouse, D., Treatment of headaches in children, Mod. Treatm., 1: 1391-1398, 1964.

228. Livingston, S., Whitehouse, D., and Pauli, L. L., Study of the effects of diphenylhydantoin sodium on the lungs, New Eng. Mod., 264: W-651, 1961.

229. Long, M. T., Childress, R. H., and Bond, W. H., Megaloblastic anemia associated with the use of anticonvulsant drugs: report of a case and review of the literature, Neurology, 13: 697-702,1963.

230. Louis, S., Kutt, H., and McDowell, F., The cardiocirculatory changes caused by intravenous Dilantin and its solvent, Amer. Heart J., 74: 523-529, 1967.

231. Louis, S., Kutt, H., and McDowell, F., Intravenous diphenylhydantoin in experimental seizures: 11. Effect on penicillin-induced seizures in the cat, Arch. Neurol., 18: 472-477, 1968.

232. Lovelace, R. E. and Horwitz, S. J., Peripheral neuropathy in long-term diphenylhydantoin therapy, Arch. Neurol., 18: 69-77, 1968.

233. L.kllmann, H. and Weber, R., On the action of Phenytoin on digitalis-induced arrhythmia, Arztliche Forschung, 22: 49-55, 1968.

234. Lustberg, A., Goldman, D., and Dreskin, 0. H., Megaloblastic anemia due to Dilantin therapy, Ann. Intem. Med., 54: 153-158, 1961.

235. McCullagh, W. M. and Ingram, W., Jr., Headaches and hot tempers, Dis. Nerv. Syst., 17: 279-281, 1956.

236. McDonald, D. B., Diphenylhydantoin and multiple system disease, Grace Hosp. Bull., 44: 40-44, 1966.

237. MacIntosh, P. C. and Hutchison, J. L., Megaloblastic anemia due to anticonvulsant therapy: report of a case responding to vitamin B12, Canad. Med. Assn. J., 82: 365-368, 1960.

238. Magee, K. R. and Wong, R. N., Complications of treatment and side reactions to anticonvulsant drugs, Mod. Treatm., I: 1138-1149,1964.

239. Malygina, E. H., Effect of phenobarbital, diphenylhydantoin and trimethadione on the blood sugar level (rabbit), Farmakol. Toksik., 28: 725-727, 1965.

240. Mandelbaum, H. and Kane, L. J., Dilantin sodium poisoning; report of a case with dermatitis exfoliativa, pyrexia and hepatic and splenic enlargement, Arch. Neurol. Psychiat., 45: 769-771, 1941.

241. Maniapaz, J. S., Abducens nerve palsy in Dilantin intoxication, J. Pediat., 55: 73-77, 1959.

242. Mark, V. H., Sweet, W. R., Ervin, F. R., Solomon, P., and Geschwind, N., Brain disease and violent behavior, Neurophthalmology, Chap. 20, 4: 282-287, J. L. Smith, ed., C. V. Mosby, St. Louis, 1968.

243. Marriott, H. J. L., Management of cardiac dysrhythmias complicating acute myocardial infarction, Geriatrics, 147-156, Sept., 1968.

244. Martin, C. M., Rubin, M., O’Malley, W. E., Garagusi, V. F., and McCauley, C. E., Comparative physiological availability of brand and generic drugs in man: chloramphenicol, sulfisoxazole, and diphenylhydantoin, Pharmacologist, 10: 167, 1968.

245. Massey, K. M., Teratogenic effects of diphenylhydantoin sodium, J. Oral Ther. Pharmacol., 2: 380-385, 1966.

246. Meeuwisse, G., Gamstorp, I., and Tryding, N., Effect of Phenytoin on the tryptophan load test, Acta Paediat. Scand., 57: 115-120, 1968.

247. Melchior, J. C. and Svensniark, O., A case of Phenytoin hypersensitivity, Acta Paediat. Scand., 52: 138-149, 1963.

248. Mercer, E. N. and Osborne, J. A., The current status of diphenylhydantoin in heart disease, Ann. Intern. Med., 67: 1084-1107, 1967.

249. Mercer, E. N., Ziegler, W. G., Wickland, G. F., and Dower, G. E., The effect of diphenylhydantoin upon beating of heart cells grown in vitro, J. Pharm. Exp. Ther., 155: 267-270, 1967.

250. Merritt, H. H. and Putnam, T. J., A new series of anticonvulsant drugs tested by experiments on animals, Arch. Neurol. Psychiat., 39: 1003-1015, 1938.

251. Mertens, H. G. and Zschocke, S., Neuromyotonia, Klin. Wschr., 17: 917-925, 1965.

252. Michels, J. G., Wright, G. C., and Gever, G., Synthesis and pharmacological activity of a series of 2-substituted pyridazinones, J. Med. Chem., 9: 612-615, 1966.

253. Middleton, J. W. and Hejtmancik, M. R., Severe leukopenia due to diphenylhydantoin sodium: case report, Texas State J. Med., 46: 520-521, 1950.

254. Millichap. J. G. and Boldrey, E. E., Studies in hyperkinetic behavior: II. Laboratory and clinical evaluations of drug treatments, Neurology, 17: 467-472, 1967.

255. Mixter, C. G., Moran, J. M., and Austen, W. G., Cardiac and peripheral vascular effects of diphenylhydantoin sodium, Amer. J. Cardiol., 17: 332-338, 1966.

256. Moore, M. T., Pulmonary changes. in hydantoin therapy, JAMA, 171: 1328-1333, 1959.

257. Morrell, F., Bradley, W., and Ptashne, M., Effect of diphenylhydantoin on peripheral nerve, Neurology, 8: 140-144, 1958.

258. Morrell, F., Bradley, W., and Ptashne, M., Effect of drugs on discharge characteristics of chronic epileptogenic lesions, Neurology, 9: 492-498, 1959.

259. Morris, J. V., Fischer, E., and Bergin, J. T., Rare complication of Phenytoin sodium treatment, Brit. Med. J.. 2: 1529, 1956.

260. Mosey, L. and Tyler, M. D., The effect of diphenylhydantoin sodium (Dilantin), procaine hydrochloride, procaine amide hydrochloride, and quinidine hydrochloride upon ouabain-induced ventricular tachycardia in unanesthetized dogs, Circulation, 10: 65-70, 1954.

261. Mull, J. D. and Mullinax, F., Diphenylhydantoin allergy: clinical and immunological studies, Arthritis Rheum., 9: 525-526, 1966.

262. Munsat, T. L., Therapy of myotonia: a double-blind evaluation of diphenylhydantoin, procainamide, and placebo, Neurology, 17: 359-367, 1967.

263. Naiman, J. G. and Williams, H. L., Effects of diphenylhydantoin on the duration of respiratory activity during anoxia, J. Pharm. Exp. Ther., 145: 34-41, 1964.

264. Nakamura, K. and Kurebe, M., Differential effects of antiepileptics on hippocampal and pallidal after discharges in cats, Jap. J. Pharmacol., 12: 180-190, 1962.

265. Nakamura, K. and Masuda, Y., Effects of 5,5-diphenylhydantoin  and   3-ethoxycarbonyl-5,5-diphenylhydantoin (P-6127) on the dermal and gingival tissues of experimental animals, Arch. Int. Pharmacodyn., 162: 255-264, 1966.

266. Nakamura, K., Masuda, Y., and Nakatsuji, K., Tissue distribution and metabolic fate of 3-ethoxycarbonyl-5,5-diphenylhydantoin (P-6127) and 5,5-diphenylhydantoin in rats, Arch. Int. Pharmacodyn., 165: 103-111, 1967.

267. Nakamura, K., Masuda, Y., Nakatsuji, K., and Hiroka, T., Comparative studies on the distribution and metabolic fate of diphenylhydantoin and 3-ethoxycarbonyl-diphenylhydantoin (P-6127) after chronic administrations to dogs and cats, Naunyn- Schmiedeberg Arch. Pharm., 254: 406-417, 1966.

268. Natelson, S., Walker, A. A., and Pincus, J. B., Chlordiazepoxide and diphenylhydantoin as antagonists to ACTH effect on serum calcium and citrate levels, Proc. Soc. Exp. Biol. Med., 122: 689-692,1966.

269. Noach, E. L., Woodbury, D. M., and Goodman, L. S., Studies on the absorption, distribution, fate and excretion of 4-C14-labeled diphenylhydantoin, J. Pharm. Exp. Ther., 122: 301-314, 1958.

270. Norris, F. H., Jr., Colella, J., and McFarlin, D., Effect of diphenythydantoin on neuromuscular synapse, Neurology, 14: 869-876,1964.

271. Oberst, B. B., Preventive care of infants and children. VI. School adjustment problems and their relationship to guided growth, J. Lancet, 86: 331-334, 1966.

272. Olesen, 0. V., Determination of phenobarbital and Phenytoin in serum by ultraviolet spectrophotometry, Scand. J. Clin. Lab. Invest., 20: 63-69, 1967.

273. Olesen, 0. V., Disulfiramum (Antabuse) as inhibitor of Phenytoin metabolism, Acta Pharmacol. Toxicol., 24: 317-322, 1966.

274. Olesen, 0. V., Determination of 5-(p-hydroxyphenyl)-5phenylhydantoin (HPPH) in urine by thin layer chromatography, Acta Pharmacol. Toxicol., 26: 222-228, 1968.

275. Olesen, 0. V., A simplified method for extracting Phenytoin from serum, and a more sensitive staining reaction for quantitative determination by thin layer chromatography, Acta Pharmacol. Toxicol., 25: 123-126, 1967.

276. Oppenheimer, J. H., Fisher, L. V., Nelson, K. M., and Jailer, J. W., Depression of the serum protein-bound iodine level by diphenylhydantoin, J. Clin. Endoc. Metab., 21: 252-262, 1961.

277. Orth, D. N., Almeida, H., Walsh, F. B., and Honda, M., Ophthalmoplegia resulting from diphenylhydantoin and primidone intoxication, JAMA, 201: 485-487, 1967.

278. Parrow, A., Use of anticonvulsive drugs in the treatment of recurrent cardiac arrhythmias, Atia Med. Scand., 180: 413-419, 1966.

279. Patil, K. P., Chitre, R. G., and Sheth, U. K., Anti-folic acid activity of anti-epileptic drugs: Part 1. Studies with bacterial cultures, Indian J. Med. Sci., 20: 614-622, 1966.

280. Pennington, G. W. and Smyth, D., Identification reactions of the hydantoin group of drugs, Arch. Int. Pharmacodyn., 152: 285-297, 1964.

281. Penny, J. L., Megaloblastic anemia during anticonvulsant drug therapy, Arch. intern. Med., 111: 744-749, 1963.

282. Peters, H. A., Eichman, P. L., Price, J. M., Kozelka, F. L., and Reese, H. H., Abnormal copper and tryptophan metabolism and chelation therapy in anti-convulsant drug intolerance, Dis. Nerv. Syst., 27: 97-106, 1966.

283. Petty, C. S., Muelling, R. J., and Sindell, H. W., Accidental, fatal poisoning with diphenylhydantoin (Ditantin), J. Forensic Sci., 2: 279-286, 1957.

284. Petty, W. C. and Karler, R., The influence of aging on the activity of anti-convulsant drugs, J. Pharm. Exp. Ther., 150: 443-448, 1965.

285. Pincus, J. H. and Giarman, N. J., The effect of diphenylhydantoin on sodium-, potassium-, magnesium-stimulated adenosine triphosphatase activity of rat brain, Biochem. Pharmacol., 16: 600-603, 1967.

286. Pincus, J. H. and Glaser, G. H., The syndrome of minimal brain damage in childhood. New Eng. J. Mod., 275: 27-35, 1966.

287. Putnam, T. J. and Hood, 0. E., Project Illinois: a study of therapy in juvenile behavior problems, Western Med., 231-233, July, 1964.

288. Raines, A. and Levitt, B., The failure of diphenylhydantoin to influence the B-adrenergic receptor of the heart, Arch. Int. Pharmacodyn., 172: 435-441, 1968.

289. Raines, A. and Standaert, F. G., Pre- and postjunctional effects of diphenylhydantoin at the cat soleus neuromuscular junction, J. Pharm. Exp. Ther., 153: 361-366, 1966.

290. Ramirez, E., The use of diphenylhydantoin in the modification of acting-out behavior of post-detoxification addict patients, Personal communication. 1967.

291. Rand, B. O., Kelly, W. A., and Ward, A. A., J r., Electrophysiological studies of the action of intravenous diphenylhydantoin (Dilantin), Neurology, 16: 1022-1032, 1966.

292. Rantakallio, P. and Furuhjelm, U., Diphenylhydantoin sensitivity: a case with exfoliative dermatitis and atypical lymphocytes in the peripheral blood, Ann. Paediat. Fenn., 8: 146-151, 1962.

293. Rawson, M. D. and Pincus, J. H., The effect of diphenylhydantoin on sodium, potassium, magnesium-activated adenosine triphosphatase in rnicrosomal fractions of rat and guinea pig brain and on whole homogenates of human brain, Biochem. Pharmacol., 17: 573-579, 1968.

294. Recant, L. and Hartroft, W. S., Lymphoma or drug reaction occurring during hydantoin therapy for epilepsy, Amer. Med., 321: 286-297, 1 962.

295. Reichelderfer, T. E., Pearson, P. H., and Livingston, S., Thrombocytopenic purpura occurring in association with paradione (paramethadione) and Dilantin sodium (Phenytoin sodium) therapy, J. Pediat., 43: 43-46, 1953.

296. Remmer, H., Estabrook, R. W., Schenkman, J., and Greim, H., Reaction of drugs with microsomal liver hydroxylase: its influence on drug action, Naunyn-Schmiedeberg Arch. Pharm., 259: 98-116, 1968.

297. Resnick, O., The psychoactive properties of diphenylhydantoin: experiences with prisoners and juvenile delinquents, Int. J. Neuropsychiat. 3: S30-S48, 1967.

298. Livingston, S., Treatment of epilepsy with diphenylhydantoin sodium (Dilantin sodium), Post-grad. Med., 20: 584-590, 1956.

299. Reynolds, E. H., Effects of folk acid on the mental state and fit-frequency of drug-treated epileptic patients, Lancet, 1: 1086-1088, 1967.

300. Reynolds, E. H., Mental effects of anticonvulsants, and folic acid metabolism, Brain, 91: 197-214, 1968.

301. Rhind, E. G. and Varadi, S., Megaloblastic anemia due to Phenytoin sodium, Lancet, 2: 921, 1954.

302. Rinne, U. K., Effect of diphenylhydantoin treatment on the release of corticotrophin in epileptic patients, Confin. Neurol., 27: 431-440, 1966.

303. Rinne, U. K., Site of the inhibiting action of diphenylhydantoin on the release of corticotrophin in epileptic patients, Med. Pharmacol. Exp., 17: 409-416, 1967.

304. Roberts, H. J., On the etiology, rational treatment and prevention of multiple sclerosis, Southern Med, J., 59: 940-950, 1966.

305. Robinow, M., Diphenylhydantoin hypersensitivity: treatment with 6-mercaptopurine, Amer. J. Dis. Child., 106: 553-557, 1963.

306. Robinson, D. S., MacDonald, M. G., and Hobin, F. P., Sodium diphenylhydantoin reaction with evidence of circulating antibodies, JAMA, 192: 171-172, 1965.

307. Robinson,L.J., The gingival changes produced by Dilantin sodium, Dis. Nerv. Syst., 3: 88-94, 1942.

308. Rosati, R. A., Alexander, J. A., Schaal, S. F., and Wallace, A. G., Influence of diphenylhydantoin on electrophysiological properties of the canine heart, Circ. Res., 21: 757-765, 1967.

309. Roseman, E., Dilantin toxicity: a clinical and electroencephalographic study, Neurology, II: 912-921, 196 1.

310. Rosen, M., Lisak, R., and Rubin, 1. L., Diphenylhydantoin in cardiac arrhythmias, Amer. J. Cardiol., 20: 674-678, 1967.

311. Rosenberg, P. and Bartels, E., Drug effects on the spontaneous electrical activity of the squid giant axon, J. Pharm. Exp. Ther., 155: 532-544, 1967.

312. Rosenfeld, S., Swiller, A. I., Shenoy, Y. M. V., and Morrison, A. N., Syndrome simulating lymphosarcoma induced by diphenylhydantoin sodium, JAMA, 176: 491-493, 1961.

313. Ross, A. T. and Jackson, V., Dilantin sodium: its influence on conduct and on psychometric ratings of institutionalized epileptics, Ann. Intern. Med., 14: 770-773, 1940.

314. Rossi, A. O., Psychoneurologically impaired child: community mental health clinic approach, New York J. Med., 67: 902-912, 1967.

315. Rowntree, L. G. and Waggoner, R. W., Prevention of migraine attacks by Dilantin sodium, Dis. Nerv. Syst., 11: 148, 1950.

316. Rudzik, A. D. and Mennear, J. H., Antagonism of anticonvulsants by adrenergic blocking agents, Proc. Soc. Exp. Biol. Med., 122: 278-280, 1966.

317. Rushton, J. G., Medical treatment of trigeminal neuralgia with a note on the results of alcohol injection, Med. Clin. N. Amer., 52: 797-800, 1968.

318. Ruthen, G. C., Antiarrhythmic drugs: Part IV. Diphenylhydantoin in cardiac arrhythmias, Amer. Heart J., 70: 275-278, 1965.

319. Ryan, G. M. S. and Forshaw, J. W. B., Megaloblastic anemia due to Phenytoin sodium, Brit. Med. J., 2: 242-243, 1955.

320. Sack, L. P., The effects of sodium Dilantin on stuttering behavior, Univ. of Calif., L. A. Doctoral thesis, 1968.

321. Said, D. M., Fraga, J. R., and Reichelderfer, T. E., Hyperglycemia associated with diphenylhydantoin (Dilantin) intoxication, Med. Ann. D.C., 37: 170-172, 1968.

322. Saltzstein, S. L. and Ackerman, L. V., Lymphadenopathy induced by anti-convulsant drugs and mimicking clinically and pathologically malignant lymphomas, Cancer, 12: 164-182, 1959.

323. Sanbar, S. S., Conway, F. J., Zweifler, A. J., and Smet, G., Diabetogenic effect of Dilantin (diphenylhydantoin), Diabetes, 16: 533, 1967.

324. Sandberg, D. H., Resnick, G. L., and Bacallao, C. Z., Measurement of serum diphenylhydantoin by gas-liquid chromatography, Anal. Chem., 40: 736-738,1968.

325. Sasyniuk, B. 1. and Dresel, P. E., The effect of diphenylhydantoin on conduction in isolated, blood-perfused dog hearts, J. Pharm. Exp. Ther., 161: 191-196, 1968.

326. Schaaf, M. and Payne, C. A., Effect of diphenylhydantoin and phenobarbital on overt and latent tetany, New Eng. J. Med., 274: 1228-1233, 1966.

327. Scherlag, B. J., Helfant, R. H., and Damato, A. N., The contrasting effects of diphenylhydantoin and procaine amide on A-V conduction in the digitalis-intoxicated and the normal heart, Amer. Heart J., 75: 200-205, 1968.

328. Scherlag, B. J., Helfant, R. H., and Damato, A. N., The relationship between the ionic, inotropic and electrophysiological effects of digitalis, Circulation, 36; 230, 1967.

329. Schneider, E., Treatment of dysrhythmic migraine and other forms of cephalagia with a new combinative preparation (Sanredo), Schweiz. Med. Wschr., 37: 1340-1343, 1963.

330. Schdn, A., Treatment with diphenylhydantoin in essential trigeminal neuralgia and in facial spasm, Gior. Psichiat. Neuropat., 92: 1011-1020, 1964.

331. Schönhärl, E., Pharmacotherapeutic experiences in speech and vocal disturbances, Med. Exp., 2: 179-183, 1960.

332. Schulte, C. J. A., and Good, T. A., Acute intoxication due to methsuximide and diphenylhydantoin, J. Pediat., 68: 635-637, 1966.

333. Schwab, R. S., Timberlake, W. H., and Abbott, J. A., Control of side effects of anticonvulsant drugs, Med. Clin. N. Amer., Boston Number, 1139-1150, 1954.

334. Serrate, J. P., Contribution to the treatment of chorea minor by diphenylhydantoin, Gac. Med. Espan., 21; 160-161, 1947.

335. Shafer, W. G., The effect of Dilantin sodium on liver DNA and restitution, J. Oral Ther. Pharm., 2: 319-323, 1966.

336. Shafer, W. G., Response of radiated human gingival fibroblast-like cells to Dilantin sodium in tissue culture, J. Dent. Res., 44: 671-677, 1965.

337. Shafer, W. G., Beatty, R. E., and Davis, W. B., Effect of Dilantin sodium on tensile strength of healing wounds, Proc. Soc. Exp. Biol, 98: 348-350, 1958.

338. Shapera, W., Dilantin therapy in certain nervous disorders, Pittsburgh Med. Bull., 29: 732-736, 1940.

339. Shapiro, M., Acceleration of gingival wound healing in non-epileptic patients receiving diphenylhydantoin sodium, Exp. Med. Surg., 16: 41-53, 1958.

340. Shulman, A. and Laycock, G. M., Action of central nervous system stimulant and depressant drugs in the intact animal: Part 3. Dual action of 5-ethyl-5-(1,3-dimethylbutyl) barbiturate, Dilantin and B-methyl-B-n-propylglutarimide, Europ. J. Phamacol., 2: 17-25, 1967.

341. Shulman, M. H., The use of Dilantin sodium in bronchial asthma: a preliminary report, New Eng. J. Med., 226: 260-264, 1942.

342. Siegel, S. and Berkowitz, J., Diphenylhydantoin (Dilantin) hypersensitivity with infectious mononucleosis-like syndrome and jaundice, J. Allergy, 32: 447-451, 1961.

343. Sklans, S., Taylor, R. G., and Shklar, G., Effect of diphenylhydantoin sodium on healing of experimentally produced fractures  in rabbit mandibles, J. Oral Surg., 25: 310-319, 1967.

344. Simpson, G. M., Kunz, E., and Slafta, J., Use of sodium diphenylhydantoin in treatment of leg ulcers, New York J. Med., 65: 886-888, 1965.

345. Simpson, W., Severe megaloblastic anemia induced by Phenytoin sodium, Oral Surg., 22: 302-305, 1966.

346. Smith, I. M., Lindell, S. S., Hazard, E. C., and Rabinovich, S., Chemical treatments of staphylococcal infections in mice, Nature, 211: 720-722, 1966.

347. Snyder, C. H., Syndrome of gingival hyperplasia, hirsutism, and convulsions: Dilantin intoxication without Dilantin, Pediat., 67: 499-502, 1965.

348. Solomon, H. M. and Schrogie, J. J., The effect of phenylramidol on the metabolism of diphenylhydantoin, Clin. ,Pharm. Ther., 8: 554-556, 1967.

349. Sparberg, M., Diagnostically confusing complications of diphenylhydantoin therapy: a review, Ann. Intem. Med., 59: 914-930,1963.

350. Standish, S. M. and Clark, P. G., The effect of Dilantin sodium on connective tissue generation in polyvinyl sponge implants, Transplantation Bull., 29: 439-445, 1962.

351. Stevens, H., Paroxysmal choreo-athetosis: a form of reflex epilepsy, Arch. Neurol., 14: 415-420, 1966.

352. Stille, G., On the question of the action of diphenylhydantoin in states of pain: a neurophysiological analysis, Nervenarzt, 31: 109-112, 1960.

353. Swan, H. and Sawyer, D. C., Prevention of ventricular fibrillation during experimental hypothermia: failure of sodium diphenylhydantoin, Arch. Surg., 95: 23-26,1967.

354. Swerdlow, B., Acute brain syndrome associated with sodium diphenylhydantoin intoxication, Amer. J. Psychiat., 122: 100-101, 1965.

355. Tec, L., Efficacy of diphenylhydantoin in childhood psychiatric disorders, Amer. J. Psychiat., 124: 156-157, 1968.

356. Theopold, W., On the use of hydantoin derivatives in chorea minor, Zschr. Kinderh., 69: 305-310, 1951.

357. Tichner, J. B. and Enselberg, C. D., Suicidal Dilantin (sodium diphenylhydantoin) poisoning, New Eng. J. Med., 245: 723-725, 1951.

358. Toman, J. E. P., Neuropharmacologic considerations in psychic seizures, Neurology, 1: 444-460, 195 1.

359. Toman, J. E. P., Drugs effective in convulsive disorders, The Pharmacological Basis of Therapeutics, 3rd Ed., 215-224, Goodman, L. S., Gilman, A., Eds., Macmillan, New York, 1965.

360. Tompsett, S. L., Note on the detection of hexoestrol, stilboestrol, dienoestrol and the p-hydroxy metabolites of phenobarbitone and Phenytoin in urine, J. Pharm. Pharmacol., 16: 207-208, 1964.

361. Triedman, H. M., Fishman, R. A., and Yahr, M. D., Determination of plasma and cerebrospinal fluid levels of Dilantin in the human, Trans. Amer. Neurol. Assn., 85: 166-170, 1960.

362. Turner, W. J., Anticonvulsive agents in the treatment of aggression, Proc. Symp. Aggressive Behavior, Milan, May 1968, 353-362, S. Garattini and E. B. Sigg, Eds., Excerpta Medica, Amsterdam, 1969.

363. Turner, W. J., Therapeutic use of diphenylhydantoin in neuroses, Int. J. Neuropsychiat., 3: 94-105, 1967.

364. Turner, W. J., The usefulness of diphenylhydantoin in treatment of non-epileptic emotional disorders, Int. J. Neuropsychiat., 3: suppl. 2, S8-S20, 1967.

365. Tuttle, R. S., and Preston, J. B., The effects of diphenylhydantoin (Dilantin) on segmental and suprasegmental facilitation and inhibition of segmental motoneurons in the cat, J. Pharm. Exp. Ther., 141: 84-91, 1963.

366. Ungar, B. and Cowling, D. C., Megaloblastic anemia associated with anticonvulsant drug therapy, Med. J. Aust., 2: 461 -462, 1960.

367. Unger, A. H. and Sklaroff, H. J., Fatalities following intravenous use of sodium diphenylhydantoin for cardiac arrhythmias: report of two cases, JAMA, 200: 335-336, 1967.

368. van Wyk, J. J. and Hoffmann, C. R., Periarteritis nodosa: a case of fatal exfoliative dermatitis resulting from “Dilantin sodium” sensitization, Arch. Intern. Med., 81: 605-611, 1948.

369. Vasko, J. S., Elkins, R. C., Fogarty, T. J., and Morrow, A. G., Effects of diphenylhydantoin on cardiac performance and peripheral vascular resistance, Surg. Forum, 17: 189-190, 1966.

370. Vastola, E. F. and Rosen, A., Suppression by anticonvulsants of focal electrical seizures in the neocortex, Electroenceph. Clin. Neurophysiol., 12: 327-332, 1960.

371. Vernadakis, A. and Woodbury, D. M., Effects of cortisol and diphenylhydantoin on spinal cord convulsions in developing rats, J.,Pharm. Exp. Ther., 144: 316-320, 1964.

372. Vincent, M. C. and Blake, M. I., A note on the analysis of diphenylhydantoin sodium by an ion exchange procedure, Drug Standards, 26: 206-207, 1958.

373. Walker, C. F. and Kirkpatrick, B. B., Dilantin treatment for behavior problem children with abnormal electroencephalograms, Amer. J. Psychiat., 103: 484-492, 1947.

374. Wallace, J., Biggs, J., and Dahl, E. V., Determination of diphenylhydantoin by ultraviolet spectrophotometry, Anal. Chem., 37: 410-413,1965.

375. Walsh, P. 1. F., Prophylaxis in alcoholics in the withdrawal period, Amer. J. Psychiat., 119: 262-263, 1962.

376. Weintraub, R. M., Pechet, L., and Alexander, B., Rapid diagnosis of drug-induced thrombocytopenic purpura, JAMA, 180: 528-532,1962.

377. Werk, E. E., Jr., MacGee, J., and Sholiton, L. J., Effect of diphenylhydantoin on cortisol metabolism in man, J. Clin. Invest., 43: 1824-1835, 1964.

378. Werk, E. E., Jr., Thrasher, K., Choi, Y., and Sholiton, L. J., Failure of metyrapone to inhibit 11-hydroxylation of 11 deoxycortisol during drug therapy, J. Clin. Endoc. Metab., 27: 1358-1360, 1967.

379. Westerink, D., Chromatographic separation and microdetermination of phenobarbital, methylphenobarbital, butobarbital and Phenytoin, Pharm. Weekbl., 97: 849-856, 1962.

380. Weidemann, D. H., New viewpoints on migraine therapy, Med. Mschr., 20: 28-30, 1966.

381. Wilske, K. R., Shalit, 1. E., Willkens, R. F., and Decker, L., Findings suggestive of systemic lupus crythematosus in subjects on chronic anticonvulsant therapy, Arthritis Rheum., 8: 260-266, 1965.

382. Wilson, D. R., Electroencephalographic studies in diabetes mellitus, Canad. Med. Assn., J., 65: 462-465, 1951.

383. Wilhoit, W. M. C., The broader treatment of acute alcoholism and delirium tremens, J. Florida Med. Assn., 52: 254-255, 1965.

384. Winiker-Blanck, E., On the diphenylhydantoin therapy of trigeminal neuralgia, Deutsch Stomat., 5: 321-322, 1955.

385. Ichikawa, J., Kimura, E., Terui, H., Wada, T., Sakurada, T., and Sakurada, S., Biochemical studies on antiepileptic drugs. 1. Effect on glucose metabolism in guinea pig brain slices, Seishin Shinkeigaku Zasshi, 69: 1089-1100, 1967.

386. Wolnisty, C., Polyneuritis of pregnancy effectively managed with Dilantin: report of a case, Obstet. Gynec., 23: 802-803, 1964.

387. Woodbury, D. M., Effect of diphenylhydantoin on electrolytes and radiosodium turnover in brain and other tissues of normal, hyponatremic and postictal rats, J. Pharm. Exp. Ther., 115: 74-95, 1955.

388. Woodbury, D. M., Effect of diphenylhydantoin on pentylene tetrazol-induced seizures in developing rats, Pharmacologist, 8: 176, 1966.

389. Woodbury, D. M. and Esplin, D. W., Neuropharmacology and neurochemistry of anticonvulsant drugs, Proc. Assn. Res. Nerv. Ment. Dis., 37: 24-57, 1959.

390. Yunis, A. A., Arimura, G. K., Lutcher, C. L., and Blasquez, J., Reversible crythroid aplasia induced by Dilantin: mechanism of action of Dilantin, J. Lab. Clin. Med., 64: 1021, 1964.

391. Yunis, A. A., Arimura, G. K., Lutcher, C. L., Blasquez, and Halloran, M., Biochemical lesion in Dilantin-induced crythroid aplasia, Blood, 30: 587-600, 1967.

392. Zeft, H. J., Whalen, R. E., Ratliff, N. B., Jr., Davenport, R. D., Jr., and McIntosh, H. D., Diphenylhydantoin therapy in experimental myocardial infarction, J. Pharm. Exp. Ther., 162: 80-84, 1968.

393. de Zeeuw, R. A. and Feitsma, M. T., Separation and identification of some barbiturates, bromoureides, Phenytoin and glutethimide by means of two-dimensional thin-layer chromatography, Pharm. Weekbl., 101: 957-976, 1966.

394. Zeiler, G., The harmine tremor-and its antagonists, Arch. Exper. Path. U. Pharmakol, 231: 34-54, 1957.

395. Zimmerman, F. T., Explosive behavior anomalies in children on an epileptic basis, New York J. Med., 56: 2537-2543, 1956.

396. Zipes, D. P. and Orgain, E. S., Refractory paroxysmal ventricular tachycardia, Ann. Intern. Med., 67: 1251-1257, 1967.

397. Zung, W. W. K., Effect of diphenylhydantoin on the sleep-dream cycle: an EEG study in normal adults, Psychophysiology, 5: 206, 1968.

398. Agarwal, S. P. and Blake, M. I., Determination of the pKa’ value for 5,5-diphenylhydantoin, J. Pharm. Sci., 57: 1434-1435, 1968.

399. Alvarez, W. C., Why patients avoid telling what is wrong, Mod. Med., 53-54, Nov. 18, 1968.

400. Rosenblum, I. and Stein, A. A., Preferential distribution of diphenylhydantoin in primary human brain tumors, Biochem. Pharmacol., 12: 1453-1454, 1963.

401. Sayar, B. and Polvan, O., Epilepsy and bronchial asthma, Lancet, 1: 1038, 1968.

402. Nayler, W. G., McInnes, I., Swann, J. B., Race, D., Carson, V., and Lowe, T. E., Some effects of diphenylhydantoin and propranolol on the cardiovascular system, Amer. Heart J., 75: 8396,1968.

403. Lüllman, H. and Weber, R., Inhibition of cardiac glycoside-induced arrhythmia by Phenytoin, Naunyn-Schmiedeberg Arch. Pharm., 259: 182-183, 1968.

404. Hilmi, K. I. and Regan, T. J., Relative effectiveness of antiarrhythmic drugs in treatment of digitalis-induced ventricular tachycardia, Amer. Heart J., 76: 365-369, 1968.

405. Mierzwiak, D. S., Mitchell, J. H., and Shapiro, W., The effect of diphenylhydantoin (Dilantin) and quinidine on left ventricular function in dogs, Amer. Heart J., 74: 780-791, 1967.

406. Mierzwiak, D. S., Shapiro, W., McNalley, M. C., and Mitchell, J. M., Cardiac effects of diphenylhydantoin (Dilantin) in man, Amer. J. Cardiol, 21: 20-22, 1968.

407. Wehrmacher, W. H., Dilantin in the management of cardi4c arrhythmias, Curr. Med. Dig., 36: 45-49, 1969.

408. Shine, K. I., Kastor, J. A., and Yurchak, P. M., Multifocal atrial tachycardia: clinical and electrocardiographic features in 32 patients, New Eng. J. Med., 279: 344-349, 1968.

409. Scuffert, G. W., Helfant, R. H., Dana, J. F., and Urbach, K. F., Use of diphenylhydantoin in prevention and treatment of cardiac arrhythmias during general anesthesia. Anesth. Analg., 47: 334-339,1968.

410. Scherf, D., Blumenfeld, S., Taner, D., and Yildiz, M., The effect of diphenylhydantoin (Dilantin) sodium on atrial flutter and fibrillation provoked by focal application of aconitine or delphinine, Amer. Heart J., 60: 936-947, 1960.

411. Carlson, E. E., Viral myocarditis, Minn. Med., 51: 829-836,1968.

412. Lawrie, D. M., Higgins, M. R., Godman, M. J., Oliver, M. F., Julian, D. G., and Donald, K. W., Ventricular fibrillation complicating acute myocardial infarction, Lancet, 2: 523-528, 1968.

413. Blachly, P. H., Diphenylhydantoin and arrhythmias, JAMA, 202; 173, 1967.

414. Editor, Hypertension in a young man, JAMA, 143: 939, 1954.

415. Conn, R. D., Newer drugs in the treatment of cardiac arrhythmia, Mod. Clin. N. Amer., 51: 1223-1240, 1967.

416. Criscitiello, M. G., Therapy atrioventricular block, New Eng. J. Med., 279: 808-810, 1968.

417. Schattenberg, T. T., Echocardiographic diagnosis of left atrial rnyxoma, Mayo Clin. Proc., 43: 620-627, 1968.

418. Bashour, F. A., Edmondson, R. E., Gupta, D. N., and Prati, R., Treatment of digitalis toxicity by diphenylhydantoin (Dilantin), Dis. Chest, 53: 263-270, 1968.

419. Chen, G., Bohner, B., and Bratton, A. C., Jr., The influence of certain central depressants on fighting behavior of mice, Arch. Int. Pharmacodyn., 142: 30-34, 1963.

420. Editor, Childhood migraine, New Eng. J. Med., 276: 5657, 1967.

421. Ginabreda, J. M. S., Treatment of chorea with diphenylhydantoin sodium, Rev. Espan. Pediat., 266-272, Mar.-Apr., 1945.

422. Roberts, H. J., Migraine and related vascular headaches due to diabetogenic hyperinsulinisin, Headache, 7: 41-62, 1967.

423. Gribetz, D., Mizrachi, A., and London, R. B., Neonatal hypocalcemia, Correspondence, New Eng. J. Med., 279: 327, 1968.

424. O’Malley, B. W. and Kohler, P. O., Hypoparathyroidism, Postgrad. Med., 44: 182-186, 1968.

425. Werk, E. E., Sholiton, L. J., and Olinger, C. P., Enzyme inducer, New Eng. J. Med., 276: 877, 1967.

426. Gilbert, J. C., Ortiz, W. R., and Millichap, J. G., The effects of anticonvulsant drugs on the permeability of brain cells to sugars, Proc. Inst. Med. Chicago, 25: May, 1965.

427. Werk, E. E., Jr., Sholiton, L. J., and Olinger, C. P., Amelioration of non-tumorous Cushing’s syndrome by diphenylhydantoin, Proc. 2nd Int. Cong. Hormonal Steroids, Excerpta Medica, No. 111, Milan, 1966.

428. Bodkin, L. G., Pruritus ani, Amer. Prac., 2: 580-581, 1948.

429. Roberts, H. J., The syndrome of narcolepsy and diabetogenic (“functional”) hyperinsulinism, with special reference to obesity, diabetes, idiopathic edema, cerebral dysrhythmias and multiple sclerosis (200 patients), J. Amer. Geriat. Soc., 12: 926-976, 1964.       

430. Fabrykant, M., Pseudohypoglycemic reactions in insulin-treated diabetics: etiology, laboratory aids and therapy, J. Amer. Geriat. Soc., 12: 221-238, 1964.

431. Ellenberg, M., Treatment of diabetic neuropathy with diphenylhydantoin, New York J. Med., 68: 2653-2655, 1968.

432. Jonas, A. D., Ictal and subictal neurosis, C. C. Thomas, Springfield, Ill., 1965.

433. Kong, Y., Chen, J. T. T., Zeft, H. J., Whalen, R. E., and McIntosh, H. D., Natural history of experimental coronary occlusion in pigs: a serial cineangeographic study, Amer. Heart J. 77: 45-54, 1969.

434. Klinefelter, H. F., Greene, C. A., Pauli, L. L. and Livingston, S., Precordial pain in an epileptic relieved by Dilantin, Johns Hopkins Med. J., 124: 25-27, 1969.

435. Bjorge, I., Presthus, J., and Stoa, K. F., A spectrophotometric study on 5,5-diphenylhydantoin, Norsk Farmaceutisk Selskap, 19: 17-22, 1957.

436. Koster, R., Mechanism of chlorcyclizine block of diphenylhydantoin in mice, Pharmacologist, 6: 187, 1964.

437. Svensmark, 0. and Kristensen, P., Determination of diphenylhydantoin and phenobarbital in small amounts of serum,  J. Lab. Clin. Med., 61: 501-507, 1963.

438. Wallace, J. E. and Dahl, E. V., New laboratory method for determining Dilantin, Air Force Systems Command Research and Technology Briefs, 3: 18-21, Sept., 1965.

439. Panalaks, T., A method for evaluation of physiological availability of diphenylhydantoin by urinary analysis, Clin. Chim. Acta, 8: 968-970, 1963.

440. Loeser, E. W., Jr., Studies on the metabolism of diphenylhydantoin (Dilantin), Neurology, 11: 424-429, 1961.

441. Schiller, P. J. and Buchthal, F., Diphenylhydantoip and phenobarbital in serum in patients with epilepsy, Danish Med. Bull., 5: 161-163,1958.

442. Burns, J. J. and Conney, A. H., Enzyme stimulation and inhibition in the metabolism of drugs, Proc. Roy. Soc. Med., 58: 955-960, 1965.

443. Butler, T. C., The metabolic conversion of 5,5-diphenylhydantoin to 5-(p-hydroxyphenyl)-5-phenylhydantoin, Pharm. Exp. Ther., 119: 1-11, 195 7.

444. Maynert, E. W., The metabolic fate of diphenylhydantoin in the dog, rat and man, J. Pharm. Exp. Ther., 130: 275-284, 1960.

445. Chang, T., Baukema, J., Dill, W. A., Buchanan, R. A., Goulet, J. R., and Glazko, A. J., Metabolic disposition of diphenylhydantoin (DPH) in human subjects following intravenous administration, Clin. Res., 16: 464, 1968.

446. Svensmark, O., Schiller, P. J., and Buchthal, F., 5, 5-diphenylhydantoin (Dilantin) blood levels after oral or intravenous dosage in man, Acta Pharmacol. (Kobenhavn), 16: 331-346, 1960.

447. Toman, J. E. P. and Taylor, J. D., Mechanism of action and metabolism of anticonvulsants, Epilepsia, Third Series, 1: 31- 48,1952.

448. Rudzik, A. D. and Mennear, J. H., The mechanism of action of anticonvulsants. 1. Diphenylhydantoin, Life Sci., 4: 2373-2382, 1965.

449. Morpurgo, C., Aggressive behavior induced by large doses of 2-(2,6-dichlorphenylamino)-2-imidazoline hydrochloride (ST-155) in mice, Europ. J. Pharmacol., 3: 374-377, 1968.

450. Sholiton, L. J., Werk, E. E., and MacGee, J., The effect of diphenylhydantoin in vitro on the metabolism of testosterone by rat liver slices, Acta Endocr., 56: 490-498, 1967.

451. Sholiton, L., Werk, E. E., Jr., and MacGee, J., The in vitro effect of 5,5 2-diphenylhydantoin on the catabolism of cortisol by rat liver, Metabolism, 13: 1382-1392, 1964.

452. Kutt, H., Verebely, K., and McDowell, F., Inhibition of diphenylhydantoin metabolism in rat liver microsomes by antituberculosis drugs, Neurology, 17: 318-319, 1967.

453. Kutt, H., Verebely, K., and McDowell, F., Inhibition of diphenylhydantoin metabolism in rats and in rat liver microsomes by antitubercular drugs, Neurology, 18: 706-710, 1968.

454. Verster, F. de B., Garoutte, J., Ichinosa, H., and Guerrero-Figueroa, R., Mode of action of diphenylhydantoin, Fed. Proc., 24: 390, 1965.

455. Elliott, K. A. C. and van Gelder, N. M., The state of factor I in rat brain: the effects of metabolic conditions and drugs, J. Physiol., 153: 423-432, 1960.

456. Shohl, J., Effects of oral administration of Dilantin sodium on abnormal behavior in the rat, J. Comp. Psychol., 37: 243-250, 1944.

457. Weissman, A., Effect of anticonvulsant drugs on clectroconvulsive shock-induced retrograde amnesia, Arch. Int. Pharmacodyn., 154: 122-130, 1965.

458. Toman, J. E. P., The neuropharmacology of antiepileptics, Electroenceph. Clin. Neurophysiol., 1: 33-44, 1949.

459. Ensor, C. R., Bohner, B., and Chen, G., Anticonvulsant effect of Dilantin sodium by intravenous administration in mice, Proc. Soc. Exp. Med. Biol., 100: 133-135, 1959.

460. Hofmann, W. W., Koenig, G., Shumway, N. E., and Hanbery, J. W., Observations of the depressant effects of parenterally administered Dilantin on the cardiovascular system and cerebral cortex, Stanford Med. Bull., 17: 193-197, 1959.

461. Riehl, J. and McIntyre, H. B., A quantitative study of the acute effects of diphenylhydantoin on the electroencephalogram of epileptic patients: Theoretical considerations for its use in the treatment of status epilepticus, Neurology, 18: 1 107-1112, 1968.

462. Schallek, W. and Kuehn, A., Effects of trimethadione, diphenylhydantoin and chlordiazepoxide on after-discharges in brain of cat, Proc. Soc. Exp. Biol. Med., 1 12: 813-816, 1963.

463. Chen, G. and Ensor, C. R., Antagonism studies on reserpine and certain CNS depressants, Proc. Soc. Exp. Biol. Med., 87: 602-608, 1954.

464. Lu, F. C., Mazurkiewicz, 1. M., Grewal, R. S., Alimark, M. G., and Boivin, P., The effect of sodium fluoride on responses to various central nervous system agents in rats, Toxic. Appl. Pharmacol., 3: 31-38, 1961.

465. Druckman, R. and Moore, F. J., Effects of sodium diphenylhydantoinate upon isolated small intestine of the rabbit, Proc. Soc. Exp. Biol. Med., 90: 173-176, 1955.

466. Van Harreveld, A. and Feigen, G. A., Effect of some drugs on the polarization state of spinal cord elements, Amer. Physiol., 160: 451-461, 1950.

467. Raines, A. and Standaert, F. G., An effect of diphenylhydantoin on post-tetanic hyperpolarization of intramedullary nerve terminals, J. Pharm. Exp. Ther., 156: 591-597, 1967.

468. Raines, A., Diphenylhydantoin suppression of post-tetanic hyperpolarization in nerve terminals of dorsal root fibers, Pharmacologist, 7: 142, 1965.

469. Brumlik, J. and Moretti, L., The effect of diphenylhydantoin on nerve conduction velocity, Neurology, 16: 1217-1218, 1966.

470. Hopf, H. C., Effect of diphenylhydantoin on peripheral nerves in man, Electroenceph. Clin. Neurophysiol., 25: 411, 1968.

471. Orozco, A. and Sabelli, H. C., Effect of antiepileptic drugs on calcium-induced hyperexcitability in earthworm ventral cords, Pharmacologist, 10: 161, 1968.

472. Korey, S. R., Effect of Dilantin and Mesantoin on the giant axon of the squid, Proc. Soc. Exp. Biol. Med., 76: 297-299, 1951.

473. Kivalo, E., Tyrkk.Ò, J., and Marjanen, P., The response to diphenylhydantoin of the neurosecretory substance in the mouse, Ann. Med. Intern. Fenn., 47: 169-173, 1958.

474. Buchthal, F., Svensmark, O., and Schiller, P. J., Clinical and electroencephalographic correlations with serum levels of diphenylhydantoin, Arch. Neurol., 2: 624-630, 1960.

475. Cohn, R., A neuropathological study of a case of petit mal epilepsy, Electroenceph. Clin. Neurophysiol., 24: 282, 1968.

476. Haury, V. G. and Drake, M. E., The effect of intravenous injections of sodium diphenylhydantoinate (Dilantin) on respiration, blood pressure, and the vagus nerve, J. Pharm. Exp. Ther., 68: 36-40, 1940.

477. Hrbek, J., Komenda, S., Dostalova, K., Siroka, A., Beran, I., and Szarowski, E., The acute effect of some drugs on the higher nervous activity in man. VII. Pyridoxine and diphenylhydantoin, Acta Univ. Palacki Olomuc., Fac. Med., 47: 625-638, 1967.

478. Takahashi, M., Effects of antiepileptic drugs on end plate region. Facilitation of acetazolamide, Hirosaki Med. J., 19: 597, 1967.

479. Van Harreveld, A., Foster, R. J., and Fasman, G. D., Effect of diphenylhydantoin on ether and pentobarbital narcosis, Amer. J. Physiol., 166: 718-722, 195 1.

480. Toman, J. E. P., Neuropharmacology of diphenylhydantoin, Int. J. Neuropsychiat., 3: S57-S62, 1967.

481. Woodbury, D. M., Effects of chronic administration of anticonvulsant drugs, alone and in combination with desoxycorticosterone, on electroshock seizure threshold and tissue electrolytes, J. Pharm. Exp. Ther., 105: 46-57, 1952.

482. Oliver, J. T. and Troop, R. C., Plasma corticosterone levels in stressed rats following the administration of pentobarbital, morphine and diphenylhydantoin, Steroids, 1: 670-677, 1963.

483. Woodbury, D. M., Timiras, P. S., and Vernadakis, A., Modification of adrenocartical function by centrally acting drugs and the influence of such modification on the central response to these drugs, Hormones, Brain Function, and Behavior, 38-50, H. Hoagland, Ed., Academic Press, New York, 1957.

484. Staple, P. H., The effects of continued administration of 5:5-diphenylhydantoin (Dilantin) sodium on the adrenal glands in mice, J. Roy. Micr. Soc., 74: 10-21, 1954.

485. Quinn, D. L., Influence of diphenylhydantoin on spontaneous release of ovulating hormone in the adult rat, Proc. Soc. Exp. Biol. Med., 119: 982-985, 1965.

486. Christy, N. P. and Hofmann, A. D., The apparent lack of effect of diphenylhydantoin (Dilantin) upon adrenal cortical response to ACTH in man, Clin. Res., 6: 258-259, 1958.

487. Takahashi, Y., Kipnis, D. M., and Daughaday, W. H., Growth hormone secretion during sleep, J. Clin. Invest., 47: 2079-2090, 1968.

488. Levy, R. P. and Marshall, J. S., Short-term drug effects on thyroid function tests, Arch. Intern. Med., 114: 413-416, 1964.

489. Zaninovich, A. A., Farach, H., Ezrin, C., and Volp6, R., Lack of significant binding of L-triiodothyronine by thyroxine binding globulin in vitro as demonstrated by acute disappearance of 131-I-labeled triiodothyronine, J. Clin. Invest., 45: 1290-1301, 1966.

490. Oppenheimer, J. H. and Tavernetti, R. R., Studies on the thyroxin-diphenylhydantoin interaction: effect of 5,5’-diphenylhydantoin on the displacement of L-thyroxine from thyroxine-binding globulin (TBG), Endocrinology, 71: 496-504, 1962.

491. Oppenheimer, J. H. and Tavernetti, R. R., Displacement of thyroxine from human thyroxine-binding globulin by analogues of hydantoin. Steric aspects of the thyroxine binding site, J. Clin. Invest., 41: 2213-2220,1962.

492. Oppenheimer, J. H., Role of plasma proteins in the binding, distribution and metabolism of the thyroid hormones, New Eng. J. Med., 278: 1153-1162, 1968.

493. Chin, W. and Schussier, G. C., Decreased serum free thyroxine concentration in patients treated with diphenylhydantoin, J. Clin. Endocrinol., 28: 181-186, 1968.

494. Mendoza, D. M., Flock, E. V., Owen, C. A., Jr., and Paris J., Effect of 5,5’-diphenylhydantoin on the metabolism of L-thyroxine-131 I in the rat. Endocrinology, 79: 106-118, 1966.

495. Merritt, H. H. and Foster, A., Vitamin C in epilepsy. Dilantin sodium not a cause of vitamin C deficiency, Amer. J. Med. Sci., 200: 541-544, 1940.

496. Gupta, D. N., Unal, M. O., Bashour, F. A., and Webb, W. R., Effects of diphenylhydantoin (Dilantin) on peripheral and coronary circulation and myocardial contractility in the experimental animal, Dis. Chest, 51: 248-255, 1967.

497. Roberts, H. J., Spontaneous leg cramps and “restless legs” due to diabetogenic hyperinsulinism: observations on 131 patients, J. Amer. Geriat. Soc., 13: 602-638, 1965.

498. Bhussry, B. R., and Rao, S., Effect of sodium diphenylhydantoinate on oral mucosa of rats, Proc. Soc. Exp. Biol. Mod., 113 : 595-599, 1963.

499. Houck, J. C., The.resorption of sodium Dilantin produced dermal collagen, J. Clin. Invest. 41: 179-184, 1962.

500. Houck, 1. C., Dermal chemical response to analogues of Dilantin, J. Invest. Derm., 40: 89-93, 1963.

501. Houck, J. C., Effect of cortisol and age upon the dermal chemical response to Dilantin, J. Invest. Derm., 40: 125-126, 1963.

502. Houck, J. C. and Jacob, R. A., Connective tissue. VII. Factors inhibiting the dermal chemical response to cortisol. Proc. Soc. Exp. Biol. Med., 113: 692-694, 1963.

503. Forscher, B. K. and Cecil, H. C., Biochemical studies on acute inflammation. II. The effect of Dilantin, J. Dent. Res., 36: 927-931, 1957.

504. Kolbert, G. S., Oral diphenylhydantoin in corneal wound healing in the rabbit, Amer. J. Ophthal., 66: 736-738, 1968.

505. Smith, D. L. and Robinson, W. A., The effect of diphenylhydantoin sodium on liver restitution in the rat following hepatectomy, Proc. West. Pharmacol. Soc., 5: 9-12, 1962.

506. Shafer, W. G., Effect of Dilantin sodium analogues on cell proliferation in tissue culture. Proc. Soc. Exp. Biol. Med., 106: 205-207, 1961.

507. Shafer, W. G., Effect of Dilantin sodium on various cell lines in tissue culture, Proc. Soc. Exp. Biol. Med., 108: 694-696, 1961.

508. Shafer, W. G., Effect of Dilantin sodium on growth of human fibroblast-like cell cultures, Proc. Soc. Exp. Biol. Med., 104: 198-201, 1960.

509. Chalmers, J. N. M. and Boheimer, K., Megaloblastic: anaemia and anticonvulsant therapy, Lancet, 2: 920-921, 1954. 510. P’an, S. Y., Funderburk, W. H., and Finger, K. F., Anticonvulsant effect of nialamide and diphenylhydantoin, Proc. Soc. Exp. Biol. Med., 108, 680-683, 196 1.

511. Conn, R. D., Kennedy, J. W., and Blackmon, J. R., The hemodynamic effects of diphenylhydantoin, Amer. Heart J., 73: 500-505,1967.

512. Rowe, G. G., McKenna, D. H., Sialer, S., and Corliss, R. J., Systemic and coronary hemodynamic effects of diphenylhydantoin, Amer. J. Med. Sci., 254: 534-541, 1967.

513. Hockman. C. H., Mauck, H. P., Jr., and Hoff, E. C., Experimental neurogenic arrhythmias, Bull. N.Y. Acad. Med., 43: 1097-1105, 1967.

514. Raines, A., Levitt, B., and Standaert, F. G., Factors influencing diphenylhydantoin antagonism of ouabain-induced ventricular arrhythmia in the cat, Pharmacologist, 9: 237, 1967.

515. Roberts, J., Levitt, B., and Standaert, F. G., Autonomic nervous system and control of cardiac rhythm, Nature, 214: 912-913, 1967.

516. Stannard, M., Sloman, G., and Sangster, L., The haemodynamic effects of Phenytoin sodium (Dilantin) in acute myocardial infarction, Med. J. Aust., 1: 335-337, 1968.

517. Lugo, V. and Sanabria, A., Treaunent of extrasystole in chronic Chagasic cardiopathy with diphenylhydantoin, Acta Medica Venezolana, 148-151, Mar.-Apr., 1966.

518. Jensen, H. P., The treatment of trigeminal neuralgia with diphenylhydantoin, Therapiewoche, 5: 345, 1955.

519. Rosati, R. and Wallace, A. G., Electrophysiologic effects of diphenylhydantoin (Dilantin) on the heart of awake dogs, Amer. J. Cardiol., 19: 147, 1967.

520. Bonnycastle, D. D. and Bradley, A. J., Diphenylhydantoin and the release of adrenocorticotropic hormone in the albino rat, Endocrinology, 66: 355-363, 1960.

521. Porter, I. H., The genetics of drug susceptibility, Dis. Nerv. Syst., 27: 25-36, 1966.

522. Bhattacharya, S. S., Kishor, K., Saxena, P. N., and Bhargava, K. P., A neuropharmacological study of gamma-aminobutyric acid (GABA), Arch. Int. Pharmacodyn., 150: 295-305, 1964.

523. de Ropp, R. S., and Snedeker, E. H., Effect of drugs on amino acid levels in brain: excitants and depressants, Proc. Soc. Exp. Biol. Med., 106: 6W700, 1960.

524. Thomas, H. F. and Stone, C. P., Maze performance of albino rats under influence of Dilantin sodium while subjected to eiectroshock, J. Psychol., 33: 127-132, 1952.

525. Blum, B., A differential action of diphenylhydantoin on the motor cortex of the cat, Arch. Int. Pharmacodyn., 149: 45-55, 1964.

526. Bianchi, C., Anticonvulsant action of some antiepileptic drugs in mice pretreated with rauwolfia alkaloids, Brit. J. Pharmacol., II: 141-146,1956.

527. Haward, L. R. C., A study of physiological responses of neurotic patients to diphenylhydantoin, Int. J. Neuropsychiat., 3: S49-S56, 1967.

528. Gerber, N. and Arnold, K., The effect of diphenyl-piperazine compounds and other agents on diphenylhydantoin, zoxazolamine and hexobarbital metabolisms. Pharm. Exp. Ther., 164: 232-238, 1968.

529. Ariyoshi, V. T. and Remmer, H., The action of phenobarbital and diphenylhydantoin on various fat fractions of liver, Naunyn-Schmiedeberg Arch. Pharm., 260: 90-91, 1968.

530. Pincus, J. H. and Rawson, M. D., Diphenylhydantoin and intracellular sodium concentration, Neurology, 19: 419-422, 1968.

531. Kemp, J. W. and Woodbury, D. M., Intracellular distribution of 4- C14 diphenylhydantoin (Dilantin) in rat brain, Pharmacologist, 4: 159, 1962.

532. Vernadakis, A. and Woodbury, D. M., Effects of diphenylhydantoin and adrenocortical steroids on free glutamic acid, glutamine, and gamma-aminobutyric acid concentrations of rat cerebral cortex, Inhibitions of the nervous system and gamma-aminobutyric acid, 242-248, Pergamon Press, Oxford, 1960.

533. Strauss, H. C., Bigger, J. T., Jr., Bassett, A. L. and Hoffman, B. F., Actions of diphenylhydantoin on the electrical properties of isolated rabbit and canine atria, Circ. Res., 23: 463-477, 1968.

534. Ludmer, R. 1. and Toman, J. E. P., Some drug effects on cardiac transmembranal potentials, Fed. Proc., 27: 303, 1968.

535. Kimball, 0. P. and Horan, T. N., The use of Dilantin in the treatment of epilepsy, Ann. Intern. Med., 13: 787-793, 1939.

536. Janz, D. and Fuchs, U., Are anti-epileptic drugs harmful when given during pregnancy?, German Med. Monthly, 9: 20-22, 1964.

537. Andia, I., Westphal, M., Anthone, R., and Anthone, S., Severe, acute diphenylhydantoin intoxication treated with peritoneal lavage, New York J. Med., 1861-1863, 1968.

538. Ayd, F. J., Jr., New uses for an old drug, Intern. Drug Ther. Newsletter, 2: 1-2, Jan., 1967.

539. Bakwin, R. M. and Bakwin, H., Psychologic aspects of pediatrics: epilepsy, J. Pediat., 39: 766-784, 1951.

540. Bergman, H., Dilantin sodium in the control of a convulsive disorder during pregnancy, Med. Rec., 155: 105-106, 1942.

541. Berlyne, N., Levene, M., and McGlashan, A., Megaloblastic anemia following anticonvulsants, Brit. Med. J., 1: 1247-1248, 1955.

542. Benians, R. C. and Hunter, R. A., Megaloblastic anemia occurring during treatment of epilepsy with Phenytoin sodium, primidone and phenobarbitone, J. Ment. Sci., 103: 606-609, 1957.

543. Braham, J., Pain in the face, Brit. Med. J.,3:316,1968.

544. Burns, J. J., Cucinell, S. A., Koster, R., and Conney, A. H., Application of drug metabolism to drug toxicity studies, Ann. N.Y. Acad. Sci., 123: 273-286, 1965.

545. Gray, W. D., Rauh, C. E. and Shanahan, R. W., The mechanism of the antagonistic action of reserpine on the anticonvulsant effect of inhibitors of carbonic anhydrase, J. Pharm. Exp. Ther., 139: 350-360, 1963.

546. Eadie, M. J., Sutherland, J. M., and Tyrer, J. H., “Dilantin” overdosage, Med. J. Aust., 2: 515, 1968.

547. Filkova, V., Hyperplastic gingivitis resulting from epilepsy treated with Phenytoin, Deutsch Stomat., 18: 294-298, 1968.

548. Fitzpatrick, T. B., Diphenylhydantoin reaction, Arch. Derm., 93: 766-767, 1966.

549. Hudgins, R. L. and Corbin, K. B., An uncommon seizure disorder: familial paroxysmal choreoathetosis, Brain, 89: 199-204, 1966.

550. Jonas, A. D., The emergence of epileptic equivalents in the era of tranquilizers, Int. J. Neuropsychiat., 3: 40-45, 1967

551. Kellaway, P.,Crawley,I.W.,and Kagawa, N., Paroxysmal pain and autonomic disturbances of cerebral origin: a specific electro-clinical syndrome, Epilepsia, 1: 466-483, 1959-1960.

552. Khoury, N. J., When alcoholics stop drinking, Postgrad. Med., 43: 119-123, 1968.

553. Kutt, H., Haynes, J., and McDowell, F., Some causes of ineffectiveness of diphenylhydantoin, Arch. Neurol., 14: 489-492, 1966.

554. Kutt, H., Winters, W., Scherman, R., and McDowell, F., Diphenylhydantoin and phenobarbital toxicity, Arch. Neurol., 11: 649-656, 1964.

555. Kutt, H., Winters, W., Kokenge, R., and McDowell, F., Diphenylhydantoin metabolism, blood levels, and toxicity, Arch. Neurol., 11: 642-648, 1964.

556. McCartan, W. and Carson, J., The use of sodium diphenylhydantoinate, J. Ment. Sci., 85: 965-971, 1939.

557. Merritt, H. H. and Putnam, T. J., Sodium diphenylhydantoinate in the treatment of convulsive disorders, JAMA, 111: 1068-1073, 1938.

558. Nelson, D. A. and Ray, C. D., Respiratory arrest from seizure discharges in limbic system, Arch. Neurol., 19: 199-207, 1968.

559. Olesen, 0. V., The influence of disulfiram and calcium carbimide on the serum diphenylhydantoin, Arch. Neurol, 16: 642-644, 1967.

560. Pasamanick, B., Anticonvulsant drug therapy of behavior problem children with abnormal electroencephalograms, A.M.A. Arch. Neurol. Psychiat., 65: 752-766, 1951.

561. Pisciotta, A. V., Penalties of progress-Drug-induced hematologic disease, Postgrad. Med., 43: 213-219, 1968.

562. Rail, L., “Dilantin” overdosage, Med. J. Aust., 2: 339, 1968.

563. Rawson, M. 1)., Diphenylhydantoin intoxication and cerebrospinal fluid protein. Neurology, 18: 1009-1011, 1968.

564. Schubert, H. A. and Malooly, D. A., Convulsive equivalent states, A.M.A. Arch. Intern. Med., 104: 585-588, 1959.

565. Tenckboff, H., Sherrard, D. J., Hickman, R. O., and Ladda, R. L., Acute diphenyihydantoin intoxication, Amer. J. Dis. Child., 116: 422-425, 1968.

566. Voigt, G. C., Death following intravenous sodium diphenylhydantoin (Dilantin), Johns Hopkins Med. J., 123: 153-157, 1968.

567. Weaver, L. C., Swinyard, E. A., and Goodman, L. S., Anticonvulsant drug combinations: diphenylhydantoin combined with other antiepileptics, J. Amer. Pharm. Assn., 47: 645-648, 1958.

568. Snyder, C. H., Syndrome of Dilantin intoxication without Dilantin, Southern Med. J., 57: 1482, 1964.

569. Roseman, E. and Klein, L. J., Epilepsy-facts and fancy, GP, 35: 144-152, 1967.

570. Landy, P. J., Lucas, B. G., and Toakley, J. G., “Dilantin” overdosage, Med. J. Aust., 2: 639-640, 1968.

571. Chafetz, M. E., Alcohol withdrawal and seizures, JAMA, 200: 195-196, 1967.

572. Editor, Cardiac arrhythmias and sodium diphenylhydantoin-an appraisal, JAMA, 201: 142-143, 1967.

573. Bonnycastle, D. D., Bonnycastle, M. F., and Anderson, E. G., The effect of a number of central depressant drugs upon brain 5-hydroxytryptamine levels in the rat, J. Pharm. Exp. Ther., 135: 17-20, 1962.

574. Garrettson, L. K., Perel, J. M., and Dayton, P. G., Methylphenidate interaction with both anticonvulsants and ethyl biscoumacetate a new action of methylphenidate, JAMA, 207: 2053-2056, 1969.

575. Bonnycastle, D. D., Paasonen, M. K., and Giarman, N.J., Diphenylhydantoin and brain-levels of 5-hydroxytryptamine, Nature, 178: 990-991, 1956.

576. Lynk, S. M. and Amidon, E., Chemotherapy with delinquents, Mich. Med., 762-766, Oct., 1965.

577. Gangloff, H. and Monnier, M., The action of anticonvulsant drugs tested by electrical stimulation of the cortex, diencephalon and rhinencephalon in the unanesthetized rabbit, Electroenceph. Clin. Neurophysiol., 9: 43-58, 1957.

578. Riley, H. D., Jr., Harris, R. L., and Nunnery, A. W., The pediatric pharmacology unit of the Children’s Memorial Hospital: studies in neonatal pharmacology, Okla. State Med. Assn. J., 61: 400-410, 1968.

579. Fromm, G. H. and Landgren, S., Effect of diphenylhydantoin on single cells in the spinal trigeminal nucleus, Neurology, 13: 34-37, 1963.

580. Franz, D. N. and Esplin, D. W., Prevention by diphenylhydantoin of post-tetanic enhancement of action potentials in nonmyelinated nerve fibers, Pharmacologist, 7: 174, 1965.

581. Fink, G. B. and Swinyard, E. A., Modification of maximal audiogenic and electro-shock seizures in mice by psychopharmacologic drugs, J. Pharm. Exp. Ther., 127: 318-324, 1959.

582. Esplin, D. W., Criteria for assessing effects of depressant drugs on spinal cord synaptic transmission, with examples of drug selectivity, Arch. Int. Pharmacodyn., 143: 479-497, 1963.

583. Kong, Y., Heyman, A., Entman, M. L., and McIntosh, H. D., Glossopharyngeal neuralgia associated with bradycardia, syncope, and seizures, Circulation, 30: 109-113, 1964.

584. Fromm, G. H. and Killian, J. M., Effect of some anticonvulsant drugs on the spinal trigeminal nucleus, Neurology, 17: 275-280, 1967.

585. Haward, L. R. C., Drugs and concentration: cognitive effect of DPH, Portsmouth J. Psychol, 1: 3-5, 1968.

586. Editor, Spasticity in multiple sclerosis, Brit. Med. J., 3: 174, 1968.

587. Michael, M. I. and Williams, J. M., Migraine in children,  J. Pediat., 41: 18-24, 1952.

588. Muniz, F. J., Lynch, J., and Nusyowitz, M. L., Diphenylhydantoin (Dilantin) induced chromosomal abnormalities, Clin. Res., 16: 310, 1968.

589. Perez del Cerro, M. and Snider, R. S., Studies on Dilantin intoxication. I. Ultrastructural analogies with the lipidoses, Neurology, 17: 452-466, 1967.

590. Russell, M. A. and Bousvaros, G., Fatal results from diphenylhydantoin administered intravenously, JAMA, 206: 2118-2119, 1968.

591. Schwartzman, J., McDonald, D. H., and Perillo, L., Sydenham’s chorea, Arch. Pediat., 65: 6-24, 1948.

592. Stein, E. and Kleinfeld, M., Effects of diphenylhydantoin on membrane potentials of Purkinje and ventricular muscle fibers in dog heart, Bull. N.Y. Acad. Med., 45: 110, 1969.

593. Geever, E. F., Seifter, E. and Levenson, S. M., Toxicity of diphenylhydantoin and its effect on wound healing in young guinea pigs, Toxic. Appl. Pharmacol., 11: 272-279, 1967.

594. Bashour, F. A., Petty, L. D., and Stephens, C. R., Value of Dilantin prophylaxis in epinephrine induced ventricular arrhythmias in the anesthetized dog, Clin. Res., 17: 14, 1969.

595. Muniz, F., Houston, E., Schneider, R., and Nusyowitz, M., Chromosomal effects of diphenylhydantoins, Clin. Res., 17: 28, 1969.

596. Nichols, R. E. and Walaszek, E. J., Antagonism of drug induced catatonia, Fed. Proc., 24: 390, 1965.

597. Bigger, T. J., Jr., Schmidt, D. H., and Kutt, H., Relationship between the plasma level of diphenythydantoin sodium and its cardiac antiarrhythmic effects, Circulation, 38: 363-374, 1968.

598. Gydesen, C. S. and Gydesen, F. R., Post micturition syndrome, Rocky Mountain Med. J., 60: 35-36, 1963.

599. McNichol, R. W., Cirksena, W. J., Payne, J. T., and Glasgow, M. C., Management of withdrawal from alcohol (including delirium tremens), Southern Med. J., 60: 7-12, 1967.

600. Pearce, K. I., Drug treatment of emotional disorders in general practice psychiatry, J. Coll. Gen. Prac. Canad., 12: 28-32, 1965.

601. Moss-Herjanik, B., Prolonged unconsciousness following electroconvulsive therapy, Amer. J. Psychiat., 124: 112-114, 1967.

602. Gordon, P. and Scheving, L. E., Covariant 24-hour rhythms for acquisition and retention of avoidance learning and brain protein synthesis in rats, Fed. Proc., 27: 223, 1968.

603. Wilson, W. P. and Wolk, M., The treatment of delirium tremens, N. Carolina Med. J., 26: 552-556, 1965.

604. Swinyard, E. A., Smith, D. L., and Goodman, L. S., Analgesic effects of clinically useful antiepileptics, J. Amer. Pharm. Assn., 43: 212-214, 1954.

605. Ende, M., Diphenylhydantoin in tic douloureux and atypical facial pain, Virginia Med. Monthly, 84: 358-359, 1957.

606. Bird, A. V., Anticonvulsant drugs and congenital abnormalities, Lancet, 1: 311, 1969.

607. Gertenrich, R. L., Fry, A. E., and Hart, R. W., The effects of Mucoplex therapy and oral hygiene on Dilantin gingival hyperplasia, Amer. J. Meng. Defic., 73: 896-902, 1969.

608. Hauser, H. M. and Brewer, E. J., Death?, Electroenceph. Clin. Neurophysiol., 23: 293, 1967.

609. Sabih, K. and Sabih, K., Chromatographic method for determination of diphenylhydantoin blood level, Anal. Chem., 4 1: 1452-1454, 1969. 

610. Schwartz, R. S., and Costea, N., Autoimmune hemolytic anemia: clinical correlations and biological implications, Sem. Hemat., 3: 2-26, 1966.

611. Reeve, H. S., Phenytoin in the treatment of trigeminal neuralgia, Lancet, 1: 404, 1961.

612. Babcock, J. R., Incidence of gingival hyperplasia associated with Dilantin therapy in a hospital population, J. Amer. Dent. Assn., 71: 1447-1450, 1965.

613. Badenoch, J.,The use of labeled vitamin Bl2 and gastric biopsy in the investigation of anemia, Proc. Roy. Soc. Med., 47: 426-431, 1954.

614. Bailey, G., Rosenbaum, J. M., and Anderson, B., Toxic epidermal necrolysis, JAMA, 191: 979-982, 1965.

615. Bajoghli, M., Generalized lymphadenopathy and hepatosplenomegaly induced by diphenylhydantoin, Pediatrics, 28: 943-945, 1961.

616. Baldi, A., Suicide through poisoning with diphenyihydantoin, Minerva Medicoleg., 74: 161-163, 1954.

617. Bernhardt, H., Fatal granulocytopenia following hydantoins-Mesantoin and Dilantin: report of a case, J. Med. Assn. Alabama, 19: 193-197, 1950.

618. Bihler, I., The sodium pump and regulation of sugar transport in skeletal muscle, Pharmacologist, 10: 198, 1968.

619. Billen, J. R., Griffin, J. W., and Waldron, C. A., Investigations for pyronin bodies and fluorescent antibodies in 5,5 diphenylhydantoin gingival hyperplasia, Oral Surg., 18: 773-782, 1964.

620. Bonard, E. C., Pseudocollagenosis or malignant pseudolymphoma, Schweiz. Med. Wschr., 94: 57-59, 1964.

621. Burton, R. C., Symptomatology-organic or psychogenic?, New York J. Med., 1304-1309, June 1, 1966.

622. Livingston, S., Seizures in a hypertensive patient, JAMA, 204:412,1968.

623. Livingston, S., Diphenylhydantoin in emotional disorders, JAMA, 204: 549, 1968.

624. Corday, E. and Vyden, J. K., Resuscitation after myocardial infarction,JAMA, 200: 781-784, 1967.

625. Cotten, M. S. and Lane, D. H., Massive strychnine poisoning: a successful treatment, J. Mississippi Med. Assn., 7: 466-468, 1966.

626. Cucinell, S. A., Conney, A. H., Sansur, M., and Burns, J. J., Drug interactions in man. 1. Lowering effect of phenobarbital on plasma levels of bishydroxycoumarin (Dicumarol) and diphenylhydantoin (Dilantin), Clin. Pharmacol. Ther., 6: 420-429, 1965.

627. Davis, R. K., Baer, P. N., and Palmer, J. H., A preliminary report on a new therapy for Dilantin gingival hyperplasia, J. Periodont., 34: 17-22, 1963.

628. Ellis, F. A., Reactions to Nirvanol, Phenytoin sodium, and phenobarbital, Southern Med. J., 36: 575-599, 1947.

629. Francis, L. E. and Melville, K. I., Effects of diphenylhydantoin on gingival histamine and serotonin, J. Canad. Dent. Assn., 25: 608-620,1959.

630. Fulop, M., Widrow, D. R., Colmers, R. A., and Epstein, E. J., Possible diphenylhydantoin-induced arrhythmia in hypothyroidisyn, JAMA, 196: 454-456, 1966.

631. Gabler, W. L., The effect of 5,5-diphenylhydantoin on the rat uterus and its fetuses, Arch. Int. Pharmacodyn., 175: 141-152,1968.

632. Gams, R. A., Neal, J. A., and Conrad, F. G., Hydantoin induced pseudo-pseudolymphoma, Ann. Intern. Med., 69: 557-568,1968.

633. Gardner-Medwin, D. and Walton, J. N., Myokymia with impaired muscular relaxation, Lancet, 1: 127-130, 1969.

634. Gianni, E. and Bracchetti, A., Pathogenesis of gingival hypertrophy caused by diphenylhydantoin in experimental animals, Minerva Stomat., 17: 609-612, 1968.

635. Gibson, J. E. and Becker, B. A., Teratogenic effects of diphenylhydantoin in Swiss-Webster and A/J mice, Proc. Soc. Exp. Biol. Med., 128: 905-909, 1968.

636. Girdwood, R. H., Folic acid, Practitioner, 199: 368-376, 1967.

637. Goldstein, L. J. and Verrastro, R., Meniere’s disease twenty years later, Eye, Ear, Nose & Throat Monthy, 46: 746-752, 1967.

638. Hamfelt, A. and Wilmanns, W., Inhibition studies on folic acid metabolism with drugs suspected to act on the myeloproliferative system, Clin. Chim. Acta, 12: 144-154, 1965.

639. Hansen, J. M., Kristensen, M., and Skovsted, L., Sulthiame (Ospolot) as inhibitor of diphenylhydantoin metabolism, Epilepsia, 9: 17-22, 1968.

640. Hoffbrand, A. V. and Necheles, T. F., Studies on the mechanism of megaloblastic anemia due to anticonvulsants, Abs. XII Cong. Int. Soc. Hematol., 92, New York, 1968.

641. Hoffbrand, A. V. and Necheles, T. F., Mechanism of folate deficiency in patients receiving Phenytoin, Lancet, 2: 528-530, 1968.

642. Hunninghake, D. B. and Azarnoff, D. L., Drug interactions with warfarin, Arch. Intern. Med., 121: 349-352, 1968.

643. Hyman, G. A. and Sommers, S. C., The development of Hodgkin’s disease and lymphoma during anticonvulsant therapy, Blood, 28: 417-427, 1966.

644. Jubiz, W., Meikle, W., West, C. D., and Tyler, F. H., Failure of dexamethasone suppression in patients on chronic diphenylhydantoin therapy, Clin. Res., 17: 106, 1969.

645. Kemp, J. W. and Woodbury, D. M., The influence of diphenylhydantoin on cerebrospinal fluid electrolytes, Pharmacologist, 8: 199, 1966.

646. Kiorboe, E., Antabuse as a source of Phenytoin intoxication, Ugeskr. Laeg., 128: 1531-1532, 1966.

647. Kokenge, R., Kutt, H., and McDowell, F., Neurological sequelae following Dilantin overdose in a patient and in experimental animals, Neurology, 15: 823-829, 1965.

648. Kruse, R., Rare, but dangerous, hydantoin side effects, Mschr. Kinderheilk., 115: 289-290, 1967.

649. Malpas, J. S., Spray, G. H., and Witts, L. J., Serum folic acid and vitamin-B12 levels in anticonvulsant therapy, Brit. Med. J, 1: 955-957, 1966.

650. Martin. D. A., The therapeutic and toxic effects of tranquilizing drugs: medical aspects, N. Carolina Med. J., 17: 396-401, 1956.

651. Kanzier, M., Malitz, S., and Higgins, J. C., How effective are antidepressants?, JAMA, 204: 34, 1968.

652. Merritt, H. H. and Putnam, T. J., Further experiences with the use of sodium diphenythydantoinate in the treatment of convulsive disorders, Amer.J.,Psychiat., 96: 1023-1027, 1940.

653. O’Quinn, S. E., The use of the indirect basophil degranulation test in the investigation of drug allergy, Southern Med. J., 58: 1147-1151, 1965.

654. Patil, K. P., Chity-e, R. G., and Sheth, U. K., Anti-folic acid activity of antiepileptic drugs. Part 2-Experimental studies in rats, Indian J. Med. Sci., 20: 623-627, 1966.

655. Plaa, G. L. and Hine, C. H., Hydantoin and barbiturate blood levels observed in epileptics, Arch. Int. Pharmacodyn., 128: 375-382,1960.

656. Ritchie, E. B. and Kalb, W., Reaction to sodium diphenylhydantoinate (Dilantin sodium) hemorrhagic erythema multiforme terminating fatally, Arch. Derm. Syph., 46: 856-.859, 1942.

657. Rosenberg, I. H., Godwin, H. A., Strieff, R. R., and Castle, W. B., Impairment of intestinal deconjugation of dietary folate: a possible explanation of megaloblastic anemia associated with Phenytoin therapy, Lancet, 2: 530-532, 1968.

658. Rümke, C. L., Increased susceptibility of mice to seizures after some anticonvulsant drugs, Europ. J. Pharmacol., 1: 369-377, 1967.

659. Rummel, W., and Wellensiek, H. J., Premedication and nitrous oxide anesthesia, Arch. Int. Pharmacodyn., 122: 339-349, 1959.

660. Sauter, E. K., Diphenylhydantoin toxicity in children, Arch. Kinderheilk,, 146: 64-70, 1953.

661. Scherf, D., Changes in the electrocardiogram after intravenous administration of Phenytoin sodium (Dilantin) in the acute experiment, Bull. N.Y. Med. Coll., 6: 82-89, 1943.

662. Slavin, R. G. and Broun, G. O. Jr., Agranulocytosis after diphenylhydantoin and chlorothiazide therapy, Arch. Intern. Med., 108: 940-944, 1961.

663. Snider, R. S. and del Cerro, M., Membranous cytoplasmic spirals in Dilantin intoxication, Nature, 212: 536-537, 1966.

664. Steinberg, S. H., Reaction to diphenylhydantoin sodium: report of a case simulating Rocky Mountain spotted fever and ,review of literature, Med. Ann. D.C., 22: 600-603, 1953.

665. Svensmark, O. and Buchthal, F., Dosage of Phenytoin and phenobarbital in children, Danish Med. Bull., 10: 234-235, 1963.

666. Svensmark, O. and Buchthal, F., Diphenylhydantoin and phenobarbital: serum levels in children, Amer. J. Dis. Child., 108, 82-87, 1964.

667. Szymanski, F. J., and McGrac, J. D., Jr., Fibrous hyperplasia of the nose, possibly related to diphenylhydantoin sodium (Dilantin) therapy, Arch. Derm., 88: 227-228, 1963.

668. Tanimukai, H., Tsukiyama, H., Yamamoto, M., and Yamada, R., A case with Hodgkin’s disease-like syndrome induced by diphenylhydantoin, Brain Nerve, 15: 77-83, 1963.

669. Strean, L. P., Treatment of ulcers, Chem. Abst. Biochem. Sec., 65: 11219c, 1966 (Merck & Co., Inc. Application for patent, Belg., May 12, 1965).

670. Block, J. D. and Moore, A. U., Hyperresponsive extinction behavior of protein-deprived pigs reduced by diphenylhydantoin (in press).

671. Turner, P., Granulocytopenia after treatment with Phenytoin sodium, Brit. Med. J., 1: 1790, 1960.

672. DaVanzo, J. P., Daugherty, M., Ruckart, R., and Kang, L., Pharmacological and biochemical studies in isolation-induced fighting mice, Psychopharmacologia, 9: 210-219, 1966.

673. Jonas, A. D., More experience with diphenylhydantoin, Amer. J. Psychiatr., 124: 1139, 1968.

674. Vernadakis, A. and Woodbury, D. M., Effects of diphenylhydantoin on electroshock seizure thresholds in developing rats, J. Pharm. Exp. Ther., 148: 144-150, 1965.

675. Waites, L. and Nicklas, T. O., Diphenylhydantoin sodium (Dilantin) intoxication in children, J. Okla. Med. Assn., 54: 95-96, 1961.

676. Wallis, W., Kutt, H., and McDowell, F., Intravenous diphenylhydantoin in treatment of acute repetitive seizures, Neurology, 18: 513-525, 1968.

677. Watanabe, S., Hypersensitivity angiitis from diphenylhydantoin, Acta Derm., (Kyoto), 59: 121-129, 1964.

678. Webster, J. M., Megaloblastic anemia due to Phenytoin sodium, Lancet, 2: 1017-1018, 1954.

679. Weintraub, M., Neonatal hypocalcemia, Correspondence, New Eng. J. Med., 279: 327, 1968.

680. Welch, B. L., Symposium on aggressive behavior, BioScience, 18: 1061-1064, 1968.

681. Wilkinson, T., Megaloblastic anemia during antiepileptic therapy, Med. J. Aust., 2: 894, 1959.

682. Levy, L. L. and Fenichel, G. M., Diphenylhydantoin activated seizures, Neurology, 15: 716-722, 1965.

683. Yen, H. C. Y., Silverman, A. J., and Salvatore, A., Iproniazid reinforcement of anticonvulsants, Fed. Proc., 19: 181, 1960.

684.  Holland, P. and Mauer, A. M., Drug-induced in vitro stimulation of peripheral lymphocytes, Lancet, 1: 1368-1369, 1964.

685. Helfant, R., Scherlag, B., and Damato, A. N., Protection from digitalis toxicity with prophylactic Dilantin: an electrophysiological-inotropic dissociation, Clin. Res., 15: 206, 1967.

686. Johnson, J., Anticonvulsants and megaloblastic anemia, J. Meng. Sci., 105: 819-820, 1959.

687. Keeran, M., Cardiac arrest following intravenous administration of diphenylhydantoin, J. Okla. Med. Assn., 60: 334-335, 1967.

688. Klein, J. P., Diphenylhydantoin intoxication associated with hyperglycemia, J. Pediat., 69: 463-465, 1966.

689. Klipstein, F. A., Folate deficiency secondary to disease of the intestinal tract, Bull. N.Y. Acad, Med., 42: 638-653, 1966.

690. Krasznai, G. and Gyory, G., Hydantoin lymphadenopathy, J. Path. Bact., 95: 314-317, 1968.

691. Levine, M. C., Lupus erythematosus and anticonvulsant drugs, Pediatrics, 33: 144-145, 1964.

692. Matthews, D. M. and Reynolds, E. H., Gastrointestinal function in anticonvulsant megaloblastic anemia, Lancet, 1: 210 -211, 1966.

693. Jonas, A. D., The distinction between paroxysmal and non-paroxysmal migraine, Headache, 79-84, July, 1967.

694. Lucas, B. G., Dilantin overdosage, Med. J. Aust., 2: 639-640,1968.

695. Toakley, J. G., Dilantin overdosage Med. J. Aust,., 2: 640, 1968.

696. Arushanyan, E. B. and Belozertsev, Y. A., Effects of diphenylhydantoin on different type of central inhibition of the knee-jerk reflex, Farmakol. Tosik., 29: 12-17, 1966.

697. Haward, L. R. C., Differential modifications of verbal aggression by psychotropic drugs, Proc. Symp. Aggressive Behavior, Milan, May, 1968, 317-321, S. Garattini and E. B. Sigg, Eds., Excerpta Medica, New York, 1969.

698. Swinyard, E. A., Weaver, L. C., and Goodman, L. S., Effect of liver injury and nephrectomy on the anticonvulsant activity of clinically useful hydantoins, J. Pharm. Exp. Ther., 104: 309-316,1952.

699. Pincus, J. H., Grove, I., Marino, B. B., and Glaser, G. E., Studies on the mechanism of action of diphenylhydantoin, Arch. Neurol., 22: 566-571, 1970.

700. Stephens, J. H. and Shaffer, J. W., A controlled study of the effects of diphenylhydantoin on anxiety, irritability, and anger in neurotic outpatients, Psychopharmacologia, 17: 169-181, 1970.

701. Davies, J. E., Edmundson, W. F., Carter, C. H., and Barquet, A., Effect of anticonvulsant drugs on dicophane (D.D.T.) residues in man, Lancet, 2: 7-9, 1969.

702. Doty, B. and Daiman, R., Diphenylhydantoin effects on avoidance conditioning as a function of age and problem difficulty, Psychos. Sci., 14: 109-111, 1969.

703. Goodman, L. S. and Gilman, A., The Pharmacological Basis of Therapeutics, 2nd Ed., 181-188, Macmillan, New York, 1955.

704. Resnick, O. and Dreyfus, J. J., Jr., Worcester County Jail study: Beneficial effects of DPH on the nervous systems of nonepileptics (condensed), Dreyfus Medical Foundation, 1966.

705. Gottwald, W., An outline of the hydantoins, Synopsis der Hydantoine (German), Forischritte der Neurologie, Psychiatrie und ihrer Grenzgebiete, 37: 573-648, 1969.

706. Baldwin, R. W., Behavior disorders in children, Maryland Med. J., 18: 68-71, 1969.

707. Dreyfus, J. J. Jr., The beneficial effects of diphenylhydantoin on the nervous systems of nonepileptics-as experienced and observed in others by a layman. Presented at the Amer. College of Neuropsychopharmacology, Dec. 7, 1966, Dreyfus Medical Foundation, 1966.

708. Rosenblum, J. A. and Shafer, N., Effects of diphenylhydantoin (Dilantin) withdrawal on non-epileptics: preliminary report, Curr. Ther. Res., 12: 31-33, 1970.

709. Haward, L. R. C., The organic integrity test as prognostic index in Phenytoin-facilitated autogenic training, World J. of Psychosynthesis, 1: 47-51, 1969.

710. Weintraub, M. I., Megahed, M. S., and Smith, B. H., Myotonic-like syndrome in multiple sclerosis, New York J. Med., 70: 677-679, 1970.

711. Bianchine, J. R., Macaraeg, P. V. J., Jr., Lasagna, L., Azarnoff, D. L.,Brunk, S. F., Hvidberg, E. F., and Owen, J. A., Jr., Drugs as etiologic factors in the Stevens-Johnson syndrome, Amer. J. Med., 44: 390-405, 1968.

712. Council on Drugs, American Medical Association Drug Evaluations, JAMA, 204, 702-710, 1968.

713. Goldberg, J. and Kurland, A. A., Dilantin treatment of hospitalized cultural-familial retardates, J. Nerv. Ment. Dis., 150: 133-137, 1970.

714. Pincus, J. H., Diphenylhydantoin and sodium influx, Neurology, 20: 393, 1970.

715. Silbermann, M., Personal communication, 1969.

716. Silverman, D., The electroencephalograph and therapy of criminal psychopaths, Criminal Psychopathology, 5: 439-457, 1944.

717. Forda, 0. and McIlwain, H., Anticonvulsants on electrically stimulated metabolism of separated mammalian cerebral cortex, Brit. J. Pharmacol., 8: 225-229, 1953.

718. Williams, J. and Stevens, H., Familial paroxysmal choreaathetosis, Pediatrics, 31: 656-659, 1963.

719. Capapas, L., Weiss, M. M., and Leight, L., The use of diphenylhydantoin sodium (Dilantin) in the treatment of cardiac arrhythmias, J. Kentucky Med. Assn., 66: 970-975, 1968.

720. Helfant, R. H., Seuffert, G. W., Patton, R. D., Stein, E., and Damato, A. N., The clinical use of diphenylhydantoin (Dilantin) in the treatment and prevention of cardiac arrhythmias, Amer. Heart J., 77: 315-323, 1969.

721. Gautam, H. P., Phenytoin in post-operative cardiac arrhythmias, Brit. Heart J., 31: 641-644, 1969.

722. Delgado, 1. M. R., Electrical stimulation of the brain,,Psychology Today, 3: 49-53, 1970.

723. Rallison, M. L., Carlisle, J. W., Lee, R. E., Jr., Vernier, R. L., and Good, R. A., Lupus crythematosus and Stevens-Johnson syndrome, Amer. J. Dis. Child., 10 1: 81-94, 196 1.

724. Hess, W. R., Interdisciplinary discussion of selected problems with reference to “The Biology of Mind,” Perspect. Biol. Med., 13: 267-293, 1970.

725. Broad range of beneficial effects of diphenylhydantain: one hundred letters, Dreyfus Medical Foundation, 1970.

726. Schmidt, R. P. and Wilder, B. J., Epilepsy: A clinical textbook, F. A. Davis Co., Phila., 150-153, 1968.

727. Vanasin, B., Bass, D. D., Mendeloff, A. I., and Schuster, M. M., Effect and site of action of diphenylhydantoin (DPH) on gastrointestinal smooth muscle, Clin. Res., 18: 391, 1970.

728. Crane, P. and Swanson, P. D., Diphenylhydantoin and the cations and phosphates of electrically stimulated brain slices, Neurology, 20: 1119-1123, 1970.

729. Sokoloff, L., The action of drugs on the cerebral circulation, Pharmacol. Rev., 11: 1-85, 1959.

730. Taylor, A. S., Behcet’s syndrome treated with DPH, Personal communication, 1969.

731. Escueta, A. V. and Appel, S. H., The effects of electrically induced seizures on potassium transport within isolated nerve terminals, Neurology, 20: 392, 1970.

732. Barasch, K., Baras, I., and Galin, M. A., Early ambulation after cataract surgery, Personal communication, 1970.

733. Padis, N., Use of DPH to control low blood sugar, Personal communication, 1967.

734. Dreifus, L. S., Use of anti-arrhythmic agents other than digitalis, J. Iowa Med. Soc., 60: 192-195, 1970.

735. Jensen, N. 0. and Olesen, V. O., The clinical importance of folic acid in patients treated with anticonvulsant drugs, Excerpta Medica, 193: 260, 1969.

736. Anthony, J. J., Malignant lymphoma associated with bydantoin drugs, Arch. Neurol, 22: 450-454, 1970.

737. Meadow, S. R., Congenital abnormalities and anticonvulsant drugs, Proc. Ray. Soc. Med., 63: 12-13, 1970.

738. Eisenberg, H., Campbell, P. C., and Flannery, J. T., Cancer in Connecticut. Incidence characteristics, 1935-1962, Conn. State Dept. of Health, Hartford, Conn., 1967.

739. Hutchins, D. A. and Rogers, K. J., Physiological and drug-induced changes in the glycogen content of mouse brain, Brit. J. Pharmacol., 39: 9-25, 1970.

740. Chen, G. and Bohner, B., A study of certain CNS depressants, Arch. Int. Pharmacodyn., 125; 1-20, 1960.

741. Millichap, J. G., Egan, R. W., Hart, Z. H., and Sturgis, L. H., Auditory perceptual deficit correlated with EEG dysrhythmias response to diphenylhydantoin sodium, Neurology, 19: 870872, 1969.

742. Covi, L., Derogatis, L. R., Uhlenhuth, E. H., and Kandel, A., Effect of diphenylhydantoin in violent prisoners, Proc. 7th Cong. of the Int. College of  Neuropsychopharmacol., Prague, 1970.

743. Cole, 1. O., Psychopharmacology: The picture is not entirely rosy, Amer. J. Psychiat., 127: 224-225, 1970.

744. Chamberlain, W., Use of diphenylhydantoin in surgery, Personal communication, 1970.

745. Eccles, J. C., The synapse, Scientific Am., 212: 56-66, 1965.

746. Galin, M. A., Kwitko, M., and Restrepo, N., The use of diphenyihydantoin in the treatment of accommodative esotropia, Proc. Int. Strabismological Assn., In Proc. Int. Ophthalmological Congress, Mexico, 1969.

747. Jaffe, N. S., Use of diphenylhydantoin in ophthalmic surgery, Personal conmunication, 1966.

748. Wilson, P. Medical News-Letter, Brit. Migraine Assn., Bournemouth, England, August, 1970.

749, Tedeschi, R. E., Tedeschi, D. H., Mucha, A., Cook, L., Mattis, P. A., and Fellows, E. J., Effects of various centrally acting drugs on fighting behavior of mice, J. Pharmacol. and Exp. Therap. 125: 28-34, 1959.

750. Alvarez, W. C., Enuresis, Modern Medicine (Editorial), 9596, June, 1969.

751. Adamska-Dyniewska, H., Evaluation of myocardial contractility after hydantoinal and ouabain based polycardiographic methods, Wiad. Lek., 23: 1749-1754,1970.

752. Adamska-Dyniewska, H., Hydantoinal-New use of an old drug, Wiad. Lek., 23: 1111-1115,1970.

753. Adamska-Dyniewska, H., The effect of diphenylhydantoin sodium given with cardiac glycosides on the left ventricular systole dynamics, Pol. Med. J., 9: 304-308, 1970.

754. Adamska-Dyniewska, H., The value of diphenylhydantoin for combating the rhythm and conduction disorders induced by cardiac glycosides, Biul. Wojskewej. Akad. Medy., 14: 7 1 77, 1971.

755. Agarwal, S. P. and Blake, M. I., Differentiating spectrophotometric titration of phenobarbital-diphenylhydantoin combinations in nonaqueous medium, Anal. Chem., 41: 1104-1106, 1969.

756. Alarcon-Segovia, D.  Fishbein, E., Reyes, P. A., Dies, H., and Shwadsky, S. Antinuclear antibiodies in patients on anticonvulsant therapy. Clin. Exp. Immunol., 12: 39-47, 1972

757. Alexander, E., Medical management of closed head injuries, Clin. Neurosurg., 19: 240-250, 1972

758.  Alexander, E., Surgical management of  head injuries in children in the acute phase. Clin. Neurosurg., 19: 251-262, 1972

759. Allen, C. D. and Klipstein, F. A., Brain folate concentration in folate-deficient rats receiving diphenylhydantoin, Neurology, 20: 403, 1970

760. Allen, J. D., Kofi Ekue, J. M., Shanks, R. G., and Zaidi, S. A., The effect on experimental cardiac arrhythmias of a new anticonvulsant agent, Ko 1173 and its comparison with phenytoin and procainarnide, Brit.. J. Pharmacol, 39: 183-184, 1970.

761. Alvarez, W. C., Nerves in collision, Pyramid House, New York, 1972.

762. American Medical Association Council on Drugs, AMA drug evaluations, 12-13 AMA, Chicago, 1971.

763. American Pharmaceutical Association, Evaluations of drug interactions, Washington, 1973.

764. Anderson, D. C., Davis, R. J., Dove, J. T., and Griggs, R. C., Cardiac conduction during treatment of myotonia, Neurology, 23: 390, 1973.

765. Anderson, R. J. and Raines, A., Suppression by Diphenylhydantoin of afferent discharges arising in muscle spindles of the triceps surae of the cat, 1. Pharmacol. Exp. Ther., 191: 290-299, 1974.

766. Anders, M. W. and Latorre, J. P., High-speed ion exchange chromatography of barbiturates, diphenylhydantoin, and their hydroxylated metabolites, Anal. Chem., 42: 1430-1432, 1970.

767. Andreasen, B., Froland, A., Skovsted, L., Andersen, S. A., and Hauge, M., Diphenylhydantoin half-life in man and its inhibition by phenylbutazone: the role of genetic factors, Acta Med. Scand., 193: 561-564, 1973.

768. Andreasen, P. B., Hansen, J. M., Skovsted, L., and Siershaek-Nielsen, K., Folic acid and the half-life of diphenylhydantoin in man, Acta Neurol. Scand., 47: 117-119, 197 1.

769. Andreasen, P. B., Hansen, J. M., Skovsted, L., and Siersbaek-Nielsen, K., Folic acid and phenytoin metabolism, Epilepsy Abstracts, 4: 221, 1971

770. Andreasen, P. B., Lyngbye, J., and Trolle, E., Tests for abnormalities in liver function during long-term diphenylhydantoin therapy in epileptic out-patients. Acta Med. Scand., 194: 261-264, 1973.

771. Ariyoshi, T. and Takabatake, E., Effect of diphenylhydantoin on the drug metabolism and the fatty acid composition of phospholipids in hepatic microsomes, Chem. Pharm. Bull., 20: 180-184, 1972.

772. Ariyoshi, T., Zange, M., and Remmer, H., Effects of diphenylhydantoin on the liver constituents and the microsomal drug metabolism enzyme systems in the partially hepatectomized rats, J. Pharm. Soc. Jap., 94: 526-530, 1974.

773. Arky, R. A., Diphenylhydantoin and the beta cell, New Eng. J. Med., 286: 371-372, 1972.

774. Arnold, K. and Gerber, N., The rate of decline of diphenylhydantoin in human plasmas Clin. Pharmacol. Ther., 11: 121-134, 1970.

775. Arnold, K., Gerber, N., and Levy, G., Absorption and dissolution studies on sodium diphenylhydantoin capsules, Canad. J. Pharm. Sci., 5: 89-92, 1970.

776. Asfeldt, V. H. and Buhl, J., Inhibitory effect of diphenylhydantoin on the feedback control of corticotrophin release, Acta Endocrinol., 61: 551-560, 1969.

777. Atkinson, A. J., Jr., Clinical use of blood levels of cardiac drugs, Mod. Conc. Cardiovasc. Dis., 42: 1-4, 1973.

778. Atkinson, A. J., Jr., Individualization of anticonvulsant therapy, Med. Clin. N. Amer., 58: 1037-1050, 1974.

779. Atkinson, A. J., Jr., MacGee, J., Strong, J., Garteiz, D., and Gaffney, T. E., Identification of 5-metahydroxyphenyl-5-phenylhydantoin as a metabolite of diphenylhydantoin, Biochem. Pharmacol., 19: 2483-2491, 1970.

780. Atkinson, A. J., Jr. and Davison, R., Diphenylhydantoin as an antiarrhythmic drug, Ann. Rev. Med., 25: 99-113, 1974.

781. Ausman, 1. I., New developments in anticonvulsant therapy, Posgrad. Med., 48: 122-127, 1970.

782. Ayala, G. F. and Lin, S., Effect of diphenylhydantoin on an isolated neuron, Fed. Proc., 30: Abstract 67, 197 1.

783. Azarnoff, D. L., Clinical implications of drug metabolism - introduction, Chem. Biol. Interactions, 3: 241-242, 197 1.

784. Azzaro, A. J. and Gutrecht, J. A., The effect of diphenylhydantoin (DPH) on the in vitro accumulation and catabolism of H3-I-norepinephrine (H3-NE) in cerebral cortex slices, Neurology, 23: 431, 1973.

785. Azzaro, A. J., Gutrecht, J. A., and Smith, D. J., Effect of diphenylhydantoin on the uptake and catabolism of L-(3H) norepinephrine in vitro in rat cerebral cortex tissue, Biochem. Pharmacol., 22: 2719-2729, 1973.

786. Babb, R. R. and Eckman, P. B., Abdominal epilepsy, JAMA, 222: 65-66, 1972.

787. Bach-Y-Rita, G., Lion, J. R., Climent, C. E., and Ervin, F. R., Episodic dyscontrol: A study of 130 violent patients, Amer. J. Psychiat., 127: 49-54, 1971.

788. Baggot, J. D. and Davis, L. E., Comparative study of plasma protein binding of diphenylhydantoin, Comp. Gen. Pharmacol., 4: 399-404, 1973.

789. Baker, T., Okamoto, M., and Riker, W. F., Diphenylhydantoin (DPH) suppression of motor nerve terminal (MNT) excitation by acetylcholine (ACh), Pharmacologist, 13: 265, 1971.

790. Baldy-Moulinier, M., Cerebral blood flow and membrane ionic pump, Europ. Neurol., 6: 107-113, 1971/72.

791. Baliek, R. E., Reidenberg, M. M., and Orr, L., Inhibition of diphenylhydantoin metabolism by chloramphenicol, Lancet, 150, 1973.

792. Baratieri, A., Gagliardi, V., and Simonetti, E., Further studies on effect of diphenylhydantoin sodium on oro facial tissues in offspring of female mice, Epilepsy Abstracts, 6: 91, 1973.

793. Barbedo, A. S., and Banks, T., Paroxysmal supraventricular tachycardia, New Eng. J. Med., 288: 51, 1973.

794. Barlow, C. F., Diphenylhydantoin-2-C14 in cat brain, J. Neuropath. Exp. Neurol., 22: 348-349, 1965.

795. Baro, W. Z., The non-convulsive convulsive disorderits diagnosis and treatment, Western Med., March, 1966.

796. Barsky, P., A clinical variant of tic convulsive  J. Pediat., 7 1: 417-419, 1967.

797. Bartter, F. C. and Schwartz, W. B., The syndrome of inappropriate secretion of antidiuretic hormone, Amer. J. Med., 42: 790-806, 1967.

798. Bashour, F. A., Coffman, G. K., and Ashby, E. A., Effect of diphenylhydantoin (Dilantin) on oxygen uptake by Sarcina lutea, Clin. Res., 14: 439, 1966.

799. Baskin, S. I. and Dutta, S., Effects of antiarrhythrnic drugs and ethacrynic acid on the accumulation of ouabain-H by the isolated guinea pig heart, Fed. Proc., 29: 739, 1970.

800. Baskin, S. I. and Dutta, S., Relationships between prevention of ouabain (O) induced arrhythmia by diphenylhydantoin (DPH) and potassium (K) and their effects on ouabain accumulation and electrolyte composition in the heart, Fed. Proc., 30: 394, 1971.

801. Baskin, S. I., Dutta, S., and Marks, B. H., The effects of diphenylhydantoin and potassium on the biological activity of ouabain in the guinea-pig heart, Brit. J. Pharmacol., 47: 85-96, 1973.

802. Baskin, S. I., Melrose, B. L., Ferguson, R. K., Akera, T., and Brody, T. M., The effect of diphenylhydantoin on ouabain induced arrhythmia and on the formation and dissociation of the ouabain-enzyrne complex, Personal Communication, 1973.

803. Bassett, A. L., Bigger, J. T., and Hoffman, B. F., Effect of diphenylhydantoin on cat heart muscle, Circulation, 35 & 36: 61,1967.

804. Bassett, A. L., Bigger, J. T., and Hoffman, B. F., Protective action of DPH on canine Purkinje fibers during hypoxia, J. Pharmacol. Exp. Ther., 173: 336-343, 1970.

805. BasuRay, B. N., Dutta, S. N., and Pradhan, S. N., Central action of ouabain: effects of propranolol and diphenylhydantoin on ouabain-induced arrhythmias, Fed. Proc., 30: Abstract 189, 1971.

806. Baugh, C. M. and Krumdieck, C. L., Effects of phenytoin on folic-acid conjugases in man, Lancet, 519-522, 1969.

807. Baughmam, F. A. and Randinitis, E. J., Passage of diphenylhydantoin across the placenta, JAMA, 213: 466, 1970.

808. Baxter, M. G., Miller, A. A., and Webster, R. A., Some studies on the convulsant action of folic acid, Brit. J. Pharmacol., 48: 350-351, 1973.

809. Baylis, E. M., Crowley, J. M., Preece, J. M., Sylvester, P. E., and Marks, V., Influence of folic acid on blood-phenytoin levels, Lancet, 1: 62-64, 197 1.

810. Baylis, E. M., Fry, D. E., and Marks, V., Micro-determination of serum phenobarbitone and diphenylhydantoin by gas. liquid chromatography, Clin. Chim. Acta, 30: 93-103, 1970.

811. Bazin, S. and Delaunay, A., Effect of phenytoin on the maturation of collagen in normal skin and granulomatous tissue, C. R. Acad. Sci. Ser. D., 275: 509-511, 1972.

812. Becker, B. and Podos, S. M., Diphenylhydantoin and its use in optic nerve disease, Symposium an Ocular Therapy, Vol. VI, I. H. Leopold, Ed., C. V. Mosby Co., St. Louis, 1973.

813. Becker, B., Stamper, R. L., Asseff, C., and Podos, S. M., Effect of diphenylhydantoin on glaucomatous field loss, Trans. Amer. Acad. Ophthal. Otolaryng., 76: 412-422, 1972.

814. Beernink, D. H. and Miller, J. J., Anticonvulsant induced antinuclear antibodies and lupus like disease in children, Epilepsy Abstracts, 6: 210, 1973.

815. Bell, W. E. and McCormick, W. F., Striatopallidonigral degeneration, Arch. Dis. Child., 46: 533-538, 1971.

816. Benaim, R., Chapelle, M., and Chiche, P., Action of diphenylhydantoin on atrioventricular and intraventricular conduction in humans, Ann. Cardiol. Angeiol., 21: 379-388, 1972.

817. Bender, F., Modern drug therapy of arrhythmia, Schweiz. Med. Wschr., 103: 272-276, 1973.

818. Bennett, W. M., Singer, I., and Coggins, C. H., Guide to drug usage in adult patients with impaired renal function, JAMA, 223: 991-997, 1973.

819. Berger, H., Fever: an unusual manifestation of epilepsy, Postgrad. Med., 40: 479-481, 1966.

820. Bergouignan, M., Antiepileptic drugs in the treatment of trigeminal neuralgia, Presse Med., 78: 1832-1834, 1970.

821. Berlin, A., Agurell, S., Borga, O., Lund, L. and Sjoqvist, F., Micromethod for the determination of diphenylhydantoin in plasma and cerebrospinal fluid, Scand. J. Clin. Invest., 29: 28 1 287, 1972.

822. Bernoulli, C., Diphenyihydantoin, Schweiz. Med. Wschr., 100: 836,1970.

823. Bernstein, J. D. and Johnson, S. L., Effects of diphenylhydantoin upon estrogen metabolism by liver microsomes of DDT-treated Japanese quail, Bull. Environ. Confam. Toxicol., 10: 309-314, 1973.

824. Berry, D. J. and Grove, J., Emergency toxicological screening for drugs commonly taken in overdose, J. Chromatogr., 80: 205-219, 1973.

825. Bhatt, G., Vijayan, N. and Dreyfus, P. M., Myotonia, Calif. Med., 114: 16-22, 1971.

826. Bigger, J. T., Jr., Steiner, C., and Burris, J. O., The effects of diphenylhydantoin on atrioventricular conduction in man, Clin. Res., 15: 196, 1967.

827. Bigger, J. T., Schmidt, D. H., and Kutt, H., A method for estimation of plasma diphenylhydantoin concentration, Amer. Heart J., 77: 572-573, 1969.

828. Bigger, J. T., Weinberg, D. I., Kovalik, T. W., Harris, P. D., Cranefield, P. C., and Hoffman, B. F., Effects of diphenylhydantoin on excitability and automaticity in the canine heart, Circ. Res., 26: 1-15, 1970.

829. Birket-Smith, E. and Krogh, E., Motor nerve conduction velocity during diphenylhydantoin intoxication, Acta. Neurol. Scand., 47: 265-271, 1971.

830. Bissett, J. K., desoyza, N. D. B., Kane, J. J., and Doherty, J. E., Case studies: effect of diphenylhydantoin on induced aberrant conduction, J. Electrocardiol., 7: 65-69, 1974.

831. Bissett, J. K., deSoyza, N. D. B., Kane, J. J., and Murphy, M. L., Improved intraventricular conduction of premature beats after diphenylhydantoin, Amer. J. Cardiol., 33: 493-497, 1974.

832. Bissett, J. K., Kane, J. J., deSoyza, N., and Doherty, J., Effect of diphenylhydantoin on bundle branch block in man, Clin. Res., 21: 405, 1973.

833. Bissett, J. K., Kane, J., deSoyza, N., and Doherty, J., Improved intraventricular conduction afterdiphenylhydantoin, Circulation, 48: 146, 1973.

834. Bittar, E. E., Chen, S. S., Danielson, B. G., and Tong, E. Y., An investigation of the action of diphenylhydantoin on sodium efflux in barnacle muscle fibres, Acta Physiol. Scand., 89: 30-38, 1973.

835. Bjerk, E. M. and Hornisher, J. J., Narcolepsy: a case report and a rebuttal, Electroenceph. Clin. Neurophysiol., 10: 550-552, 1958.

836. Black, J. T., Garcia-Mullin, R., Good, E., and Brown, S., Muscle rigidity in a newborn due to continuous peripheral nerve hyperactivity, Arch. Neurol., 27: 413-425, 1972,

837. Black, N. D., The value of diphenylhydantoinate (Dilantin) in psychoses with convulsive disorders, Psychiatr. Quart., 13: 711-720, 1939.

838. Blum, M. R., McGilveray, I., Becker, C. E., and Riegelman, S., Clinical implications derived from pharmacokinetics of diphenylhydantoin (DPH), Clin. Res., 19: 121, 197 1.

839. Blum, M., Riegelman, S., and Becker, C. E., Altered protein binding of diphenylhydantoin in uremic plasma, New Eng. Med., 286: 109, 1972.

840. Blumenkrantz, N. and Asboe-Hansen, G., Effect of diphenylhydantoin on connective tissue, Acta Neurol, Scand., 50: 302-306, 1974.

841. Bochner, F., Hooper, W. D., Sutherland, J. M., Eadie, M. J., and Tyrer, J. @l., The renal handling of diphenylhydantoin and 5-(P-Hydroxyphenyl)-5-phenylhydantoin, Clin. Pharmacol. Ther., 14: 791-796, 1973.

842. Bochner, F., Hooper, W. D., Tyrer, J. H., and Eadie, M. J., Effect of a delayed-action phenytoin preparation on blood phenytoin concentration, J. Neurol. Neurosurg. Psychiat., 35: 682684, 1972.

843. Bochner, F., Hooper, W. D., Sutherland, J. M., Eadie, M. J., and Tyrer, J. H., Diphenylhydantoin concentrations in saliva, Arch. Neurol., 31: 57-59, 1974.

844. Bochner, F., Hooper, W. D., Tyrer, J. H., and Eadie, M. J., Factors involved in an outbreak of phenytoin intoxication, Epilepsy Abstracts, 5: 245-246, 197 1.

845. Bochner, F., Hooper, W., Tyrer, J., and Eadic, M., Clinical implications of certain aspects of diphenylhydantoin metabolism, Proc. Aust. Assoc. Neurol., 9: 171-178, 1973.

846. Bogoch, S. and Dreyfus, J., The broad range of use of diphenylhydantoin, bibliography and review, The Dreyfus Medical Foundation, 1970.

847. Booker, H. E., Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication, Epilepsia, 14: 96-97, 1973.

848. Booker, H. E., Tormey, A., and Toussaint, J., Concurrent administration of phenobarbital and diphenylhydantoin: lack of an interference effect, Neurology, 21: 383-385, 197 1.

849. Borga, O., et a], Plasma protein binding of tricyclic antidepressants in man, Psychopharm. Abs., 9: 500, 1970.

850. Borga, O., Garle, M., and Gutova, M., Identification of 5-(3, 4-dihydroxyphenyl)-5-phenylhydantoin as a metabolite of 5, 5-diphenylhydantoin (phenytoin) in rats and man, Pharmacology, 7: 129-137, 1972.

851. Borgstedt, A. D., Bryson, M. F., Young, L. W., and Forbes, G. B., Long-term administration of antiepileptic drugs and the development of rickets, J. Pediat., 81: 9-15, 1972. (cf. Greenlaw, et al., Clin. Res., 20: 56, 1972.)

852. Borofsky, L. G., Louis, S., and Kutt, H., Diphenylhydantoin in children, Neurology, 23: 967-972, 1973.

853. Borondy, P., Dill, W. A., Chang, T., Buchanan, R. A., and Glazko, A. J., Effect of protein binding on the distribution of 5, 5-diphenylhydantoin between plasma and red cells, Ann. N.Y. Acad. Sci., 226: 82-87, 1973.

854. Bose, B. C., Gupta, S. S., and Sharma, S., Effect of anticonvulsant drugs on the acetylcholine content in rat tissues, Arch. Int. Pharmacodyn., 67: 254-261, 1958.

855. Boshes, B. and Arieff, A. J., Clinical experience in the neurologic substance of pain, Med. Clin. N. Amer., 52: 111-121, 1968.

856. Boston Collaborative Drug Surveillance Program, Diphenylhydantoin side effects and serum albumin levels, Clin. Pharmacol. Ther., 14: 529-532, 1973.

857. Boudin, G., Pepin, B., Decroix, G., and Vernant, J. C., Diphenylhydantoin intoxication triggered by antituberculous treatment (2 cases), Ann. Med. Intern., 122: 855-860, 197 1.

858. Bouzarth, W. F., The ABC’s of emergency care of serious head injuries in industry, Industr. Med. Surg., 39: 25-29, 1970.

859. Bowe, J. C., Cornish, E. J., and Dawson, M., Evaluation of folic acid supplements in children taking phenytoin, Develop. Med. Child Neurol., 13: 343-354, 197 1.

860. Boyd, D. L. and Williams, J. F., The effect of diphenylbydantoin (Dilantin) on the positive inotropic action of ouabain, Amer. J. Cardiol., 23: 712-718, 1969.

861. Boykin, M. E. and Hooshmand, H., CSF and serum folic acid and protein changes with diphenylhydantoin treatment: laboratory and clinical correlations, Neurology, 20: 403, 1970.

862. Boykin, M. E., In vivo and in vitro association of 5, 5diphenylhydantoin with brain subtractions, Neurology, 4: 392-393, 1974.

863. Bozza, G. A., Normalization of intellectual development in the slightly brain-damaged, retarded child, Paper presented at the 4th Italian National Congress on Child Neuropsychiatry, Genoa, 1971.

864. Bray, P. F., Ely, R. S., and Kelley, V. C., Studies of 17-hydroxycorticosteroids VIII. Adrenocortical function in patients with convulsive disorders, A.M.A. Arch. Neurol. Psychiat., 72: 583-590, 1954.

865. Bray, P. F., Ely, R. S., Zapata, G., and Kelley, V. C., Adrenocortical function in epilepsy 1. The role of cortisol (hydrocortisone) in the mechanism and management of seizures, Neurology, 10: 842-846, 1960.

866. Bray, P. F., Kelley, V. C., Zapata, G., and Ely, R. S., Adrenocortical function in epilepsy II. The role of corticosterone in the mechanism and management of epilepsy, Neurology, 11: 246250, 1961.

867. Brena, S. and Bonica, Nerve blocks for managing pain in the elderly, Postgrad. Med., 47: 215-220, 1970.

868. Brennan, R. W., Dehejia, H., Kutt, H., Verebely, K., and McDowell, F., Diphenylhydantoin intoxication attendant to slow inactivation of isoniazid, Neurology, 20: 687-693, 1970.

869. Brien, J. F. and Inaba, T., Determination of low levels of 5,5-diphenylhydantoin in serum by gas liquid chromatography, Epilepsy Abstracts, 7: 198, 1974.

870. Bright, N. H., Effect of diphenylhydantoin on proline and hydroxyproline excretion in the rat, Proc. Soc. Exp. Biol. Med., 120: 463-465, 1965.

871. Broddle, W. D., and Nelson, S. R., The effect of diphenylhydantoin on brain P-creatine, Fed. Proc., 28: 1771, 1969.

872. Brodows, R. G. and Campbell, R. G., Control of refractory fasting hypoglycemia in a patient with suspected insulinoma with diphenylhydantoin, J. Clin. Endocr., 38: 159-161, 1974.

873. Brown, G. L., and Wilson, W. P., Salicylate intoxication and the CNS with special reference to EEG findings, Dis. Nerv. Syst., 32: 135-140, 1971.

874. Brown, J. M., Drug-associated lymphadenopathies with special reference to the Reed-Sternberg cell, Med. J. Aust., 375-378, 1971.

875. Buchanan, R. A., and Allen, R. J., Diphenylhydantoin (Dilantin) and phenobarbital blood levels in epileptic children, Neurology, 21: 866-871, 1971.

876. Buchanan, R. A., Kinkel, A. W., Goulet, J. R., and Smith, T. C., The metabolism of diphenylhydantoin (Dilantin) following once-daily administration, Neurology, 22: 126-130, 1972.

877. Buchanan, R. A., Turner, J. L., Moyer, C. E., and Heffelfinger, J. C., Single daily dose of diphenylhydantoin in children, J Pediat., 83: 479-483, 1973.

878. Buchthal, F. and Lennox-Buchthal, M. A., Diphenylhydantoin, relation of anticonvulsant effect to concentration in serum, Antiepileptic Drugs, 193-209, Woodbury, D. M., Penry, K., and Schmidt, R. P., Eds., Raven Press, New York, 1972

879. Buchthal, F. and Svensmark, O., Serum concentrations of diphenylhydantoin (phenytoin) and phenobarbital and their relation to therapeutic and toxic effects, Psychiat. Neurol. Neurochir., 74: 117-136, 1971.

880. Burckhardt, D. and Sefidpar, M., Digitalis intoxication: contribution to diagnosis and therapy, Schweiz. Rundschau. Med. (Praxis), 60: 1705-1711, 1971.

881. Buscaino, G. A., Labianca, O., Caruso, G., De Giacomo, P., and Ferrannini, E., Electromyographic and muscular histoenzymatic findings in a patient with continuous muscular activity syndrome (“Neuromyotonia”), Acta Neurol (Naples), 25: 206-224, 1970.

882. Calne, D. B., The drug treatment of epilepsy, Epilepsy Abstracts, 6: 177, 1973.

883. Cantor, F. K., Phenytoin treatment of thalamic pain. Brit. Med. J., 4: 590-591, 1972.

884. Caracia, A. R., Damato, A. N., Josephson, M. E., Ricciutti, M. A., Gallagher, J. J., and Lau, S. H., Electrophysiologic properties of diphenylhydantoin, Circulation, 4.7: 1234-1241, 1973.

885. Carnay, L. and Grundfest, S., Excitable membrane stabilization by diphenylhydantoin and calcium, Neuropharmacology, 13: 1097-1108, 1974.

886. Caspary, W. F., Inhibition of intestinal calcium transport by diphenylhydantoin in rat duodenum, Epilepsy Abstracts, 6: 18, 1973.

887. Castleden, C. M., and Richens, A., Chronic phenytoin therapy and carbohydrate tolerance, Lancet, 966-967, 1973.

888. Chang, T; and Glazko, A. J., Diphenylhydantoin biotransformation, Antiepileptic Drugs, 149-162, Woodbury, D. M., Penry, J. K., and Schmidt, R. P., Eds., Raven Press, New York, 1972.

889. Chang, T., Okerholm, R. A., and Glazko, A. J., A 3-0methylated catechol metabolite of diphenylhydantoin (Dilantin) in rat urine, Res. Communications Chem. Path. Pharmacol., 4: 13-23, 1972.

890. Chang, T., Savory, A. and Glazko, A. J., A new metabolite of 5, 5-diphenylhydantoin (Dilantin),-Biochem. Biophys. Res. Commun., 38: 444-449, 1970.

891. Cheng, P. T. H. and Staple, P. H., Effect of a dorsal dermal surgical wound on the chemical response of rat abdominal skin to chronic administration of sodium diphenylhydantoin, J. Dent. Res., 51: 131-143, 1972.

892. Cheng, T. 0. and Damato, A. N., Dilantin in treatment and prevention of cardiac arrhythmias, Amer. Heart J., 78: 285, 1969.

893. Chetchel, A. P., The influence of diphenine on the gum mucosa, Epilepsy Abstracts, 3: 203, 1970.

894. Chikhani, P., The use of  “diphenylhydantoin sodium” in the treatment of periodontal disease, Actualities Odonto-Stomat, 98: 1-8, 1972.

895. Choi, Y. K. and Kee, C. S., Induction of steroid 6 betahydroxylase by administration of diphenylhydantoin, Chem. Abstracts, 74: 123576C, 1971.

896. Choi, Y., Thrasher, K., Werk, E. E., Sholiton, L. J., and Olinger, C., Effect of diphenylhydantoin on cortisol kinetics in humans, J. Pharmacol. Exp. Ther., 176: 27-34, 1971.

897. Chokroverty, S. and Rubino, F. A., Motor nerve conduction study in patients on long term diphenylhydantoin therapy: correlation with clinical states and serum levels of diphenyihydantoin, folate and cyanocobalamine, Epilepsy Abstracts, 7: 111,  1974.

898. Choovivathanavanich, P., Wallace, E. M., and Scaglione, P. R., Pseudolymphoma induced by diphenylhydantoin, J. Pediat., 76: 621-623, 1970.

899. Chou, C. C., Kuiper, D. H., and Hsieh, C. P., Effects of diphenylhydantoin on motility and compliance of the canine ileum and colon, Gastroenterology, 62: 734, 1972.

900. Chriskie, H. W., du Mesnil de Rochemont, W., Etzrodt, H., Grosser, K. D., Schulten, K. H., and Steinbruck, G., Influ- ence of diphenylhydantoin and lidocaine on hemodynamics in patients with fixed-rate pacemakers, Verh. Deutsch Ges. Inn. Med., 77: 960-963, 1971.

901. Christiansen, C., Rodbro, P., and Lund, M., Effect of vitamin D on bone mineral mass in normal subjects and in epileptic patients on anticonvulsants: a controlled therapeutic trial, Brit. Med. J., 208-209, 1973. (cf. Christiansen, et al., Brit. Med. J., 3: 738, 1972 and Brit. Med. J., 4: 695, 1973.)

902. Christiansen, J. and Dam, M., Influence of phenobarbital and diphenyihydantoin on plasma carbamazepine levels in patients with epilepsy, Epilepsy Abstracts, 7: 137, 1974.

903. Christy, N. P. and Hofmann, A. D., Effects of diphenylhydantoin upon adrenal cortical function in man, Neurology, 9: 245-248, 1959.

904. Chrobok, F., Quantitative determination of phenytoin in biological material in the presence of phenobarbital and glutethimide, Epilepsy Abstracts, 5: 172, 1972.

905. Chung, E. K., The current status of digitalis therapy, Modem Treatment, 8: 643-714, 1971.

906. Clark, R. L., Kuhn, J. P., and Du jovne, C. A., Absence of rickets after chronic dilantin administration: experimental radiological observations in rats, Invest. Radiol., 6: 152-154, 197 1.

907. Coburn, R. F., Enhancement by phenobarbital and diphenylhydantoin of carbon monoxide production in normal man, New Eng. J. Mod., 283: 512-515, 1970.

908. Cohen, H., Langendorf, R., and Pick, A., Intermittent parasystole-mechanism of protection, Circulation, 48: 761-774,1973.

909. Cohen, M. S., Bower, R. H., Fidler, S. M., Johnsonbaugh, R. E., and Sode, J., Inhibition of insulin release by diphenylhydantoin and diazoxide in a patient with benign insulinoma, Lancet, 40-41, 1973.

910. Cole, P., Efficacy of oral diphenylhydantoin in reduction of premature ventricular contractions, Clin. Pharmacol. Ther., 13: 137, 1972.

911. Collan, R., Boyd, W., and Hathaway, B., Effect of halothane on the liver of rats pretreated with diphenylhydantoin and norethindrone, Scand. J. Clin. Lab. Invest., 25: 74, 1970.

912. Conn, H. L., Jr., Mechanisms of quinidine action. Mechanisim and Therapy of Cardiac Arrhythmias, 594-596, Dreifus, L. S. and Ukoff, W., Eds., Grune and Stratton, New York, 1966.

913. Conners, C. K., Kramer, R., Rothschild, G. H., Schwartz, L., and Stone, A., Treatment of young delinquent boys with diphenylhydantoin sodium and rnethyphenidate, Arch. Gen. Psychiat., 24: 156-160, 1971.

914. Conney, A. H. and Burns, Metabolic interactions among environmental chemicals and drugs, Science, 178: 576-586, 1972.

915. Conney, A. H., Jacobson, M., Schneidman, K., and Kuntzman, R., Induction of liver microsomal cortisol 6 .²-hydroxylase by diphenylhydantoin or phenobarbital: an explanation for the increased excretion of 6-hydroxycortisol in humans treated with these drugs, Life Sci., 4: 1091-1098, 1965.

916. Conard, G. J., Haavik, C. O., and Finger, K. F., Binding of 5,5-diphenylhydantoin and its major metabolite to human and rat plasma proteins, J. Pharm. Sci., 60: 1642-1646, 197 1.

917. Cooper, R. G., Greaves, M. S., and Owen, G., Gas liquid chromatographic isolation, identification, and quantitation of some barbiturates, glutethimide, and diphenylhydantoin in whole blood, Epilepsy Abstracts, 6:, 184, 1973.

918. Costa, P. J., Glaser, G. H., and Bonnycastle, D. D., Effects of diphenylhydantoin (Dilantin) on adrenal cortical function, A.M.A. Arch. Neurol. Psychiat., 74: 88-91, 1955.

919. Covi, L. and Uhlenhuth, E. H., Methodological problems in the psychopharmacological study of the dangerous anti-social personality, Proc. Int. Symposium an Aggressive Behavior Biochem. Pharmacol Psychol. Sociol, 326-335, May, 1969.

920. Covino, B. G., Wright, R., and Charleson, D. A., Effectiveness of several antifibrillary drugs in the hypothermic dog, Amer. J. Physiol., 121: 54-58, 1955.

921. Cranmer, M. F., Effect of diphenylhydantoin on storage of DDT in the rat, Toxic Appl. Pharmacol., 17: 315, 1970.

922. Critchicy, E. M. R., Clark, D. B., and Wikier, A., An adult form of acanthocytosis, Trans. Amer. Neurol. Assoc., 92: 132-137, 1967.

923. Cuan-Perez, M. C. and Ortiz, A., Comparative study of quinidine, propranolol and diphenylhydantoin for preventing recurrence in post-cardioversion auricular fibrillation, Arch. Inst. Cardiol. Mex., 41: 278-284, 1971.

924. Cudworth, A. G. and Cunningham, J. L., The effect of diphenylhydantoin on insulin response, Clin. Sci. Molec. Med., 46: 131-136, 1974.

925. Cummings, N. P., Rosenbloom, A. L., Kohler, W. C. and Wilder, B. J., Plasma glucose and insulin responses to oral glucose with chronic diphenyihydantoin therapy, Pediatrics, 51: 1091-1093, 1973.

926. Cunningham, J. L. and Price Evans, D. A., Urinary D-glucaric acid excretion and acetanilide pharmacokinetics before and during diphenylhydantoin administration, Europ. J. Clin.,Pharmacol., 7: 387-391, 1974.

927. Curtis, G. P., Experimental atrial fibrillation, Univ. of Mich., Ann Arbor, Doctoral Thesis, 197 1.

928. Dack, S., Antiarrhythmic agents in the treatment of ventricular tachycardia, Mechanisms and Therapy of Cardiac Arrhythmias, 312-320, Dreifus, L. S. and Ukoff, W., Eds., Grune and Stratton, New York, 1966.

929. Dalessio, D. J., Medical treatment of tic douloureux, Chronic Dis., 19: 1043-1048, 1966.

930. Dalton, C. and Verebely, K., Hypotriglyceridemic activity of 5,5’-diphenyl-2-thiohydantoin (DPTH), J. Pharmacol. Exp. Ther., 180: 484-491, 1971.

931. Daly, R. F. and Sajor, E. E., Inherited tic douloureux, Neurology, 23: 937-939, 1973.

932. Dam, M. and Christiansen, J., Evidence of drug action on serum level of carbamazepine, Epilepsy Abstracts, 7: 26, 1974.

933. Dam, M., Diphenylhydantoin, neurologic aspects of toxicity, Antieplipetic Drugs, 227-235, Woodbury, D. M., Penry, J. K., and Schmidt, R. P. Eds., Raven Press, New York, 1972.

934. Dam, M., The density and ultrastructure of the Purkinje cells following diphenylhydantoin treatment in animals and man, Acta Neurol. Scand., 48: 1-65, 1972.

935. Damato, A. N., Berkowitz, W. D., Patton, R. D., and Lau, S. H., The effect of diphenylhydantoin on atrioventricular and intraventricular conduction in man, Amer. Heart J., 79: 51-56, 1970.

936. Damato, A. N., Diphenylhydantoin: pharmacological and clinical use, Progr. Cardiovasc. Dis., 12: 1-15, 1969.

937. Danckwardt-Ulliestrom, G., Grevsten, S., and Olerud, S., Investigation of effect of various agents on periosteal bone formation, Upsala J. Med. Sci., 77: 125-128, 1972.

938. Daniel, R., Psychiatric drug use and abuse in the aged, Geriatrics, 144-156, January, 1970.

939. Daniels, C., Stein, A. A., and Moss, G., The shock lung syndrome: anemia as a predisposing factor, Surg. Forum, 24: 1, 1973.

940. Danielson, B. G., Bittar, E. E., Chen, S. S. and Tong, E. Y., Diphenylhydantoin as a blocking agent of the proton-sensitive component of Na efflux in barnacle muscle fibers, Life Sci., 10: 721-726, 1971.

941. Danzig, R., Treatment of arrhythmias associated with acute myocardial infarction, Nebraska Med. J., 56: 474-475, 1971. 

942. Daube, J. R., and Peters, H. A., Hereditary essential myoclonus, Arch. Neurol., 15: 587-594, 1966.

943. Davies, J. E., Edmundson, W. F., Maceo, A., Irvin, G. L., Cassady, J., and Barquet, A., Reduction of pesticide residues in human adipose tissue with diphenylhydantoin, Food Cosmet. Toxic., 9: 413-423, 1971.

944. Davies, J. E., Pharmacological depletion of adipose pesticide residues, Clin. Res., 19: 27, 197 1.

945. Davies, R. O., Diphenylhydantoin in angina pectoris, Chest, 66: 421-422, 1974.

946. Davis, J. N.. Diphenylhydantoin for hiccups, Lancet, 1: 997, 1974.

947. Dawson, K. P., and Jamieson, A., Value of blood phenytoin estimation in management of childhood epilepsy, Arch. Dis. Child., 46: 386-388, 197 1.

948. Dawson, K. P., Severe cutaneous reactions to phenytoin, Arch. Dis. Child., 48: 239-240, 1973.

949. Day, H. W., Control and treatment of arrhythmias, Cardiovascular Therapy, The Art and The Science, 289-291, Russek, H. I., and Zohman, B. L., Eds., The Williams & Wilkins Co., Baltimore, 1971.

950. DeCastro, J. H. X., Acosta, M. L., Sica, R. E. P., and Guerico, N., Sensory and motor nerve conduction velocity in long-term diphenylhydantoin therapy, Arq. Neuropsiquiat., 30: 215-220,1972.

951. DeLuca, K., Masotti, R. E., and Partington, M. W., Altered calcium metabolism due to anticonvulsant drugs, Develop. Med. Child Neurol., 14: 318-321, 1972.

952. Delaire, J., Moutet, H., and Talmant, J. C., Facial peripheric hemispasm and Paget’s disease of bone, Rev. Stomat. (Paris), 73: 601-612, 1972.

953. Delgado, J. M. R. and Mihailovic, L., Use of intracerebral electrodes to evaluate drugs that act on the central nervous system, Ann. N.Y. Acad. Sci., 64: 644-666, 1956.

954. Delgado, J. M. R., Mora, F. and Sanguinetti, A. M., Reduction by diphenylhydantoin of after-discharges in the amygdala of stimulated rhesus monkey, Personal Communication, 1973.

955. Den Hertog, A., The effect of diphenylhydantoin on the electronic component of the sodium pump in mammalian nonmyelinated nerve fibers, Europ. J. Pharmacol., 19: 94-97, 1972.

956. Dent, E., Richens, A., Rowe, D. J. F., and Stamp, T. C. B., Osteomalacia with long-term anticonvulsant therapy in epilepsy, Brit. Med. J., 4: 69-72, 1970.

957. Desjacques, P., Study of the diffusion of phenytoin through the cellophane membrane of the artificial kidney used on a patient suffering from uremia and epilepsy, Epilepsy Abstracts, 5: 220, 1972.

958. De Sousa, R. C. and Grosso, A., Effects of diphenyihydantoin on transport processes in frog skin (Rana ridibunda), Epilepsy Abstracts, 7: 111, 1974.

959. dewolff, F. A., Drug effects on intestinal epithelium, Doctoral Thesis, 1973.

960. Dhar, G. J., Peirach, C. A., Ahamed, P. N., and Howard, R. B., Diphenylhydantoin induced hepatic necrosis, Postgrad. Med., 56: 128-129, 1974.

961. Diamond, B. and Yaryura-Tobias, J. A., The use of diphenylhydantoin in non-epileptic psychotics, V World Congress of Psychiatry, 1971.

962. Diamond, W. D. and Buchanan, R. A., A clinical study of the effect of phenobarbital on diphenylhydantoin plasma levels, J. Clin. Pharmacol., 306-311, 1970.

963. Diederich, K. W., Herzog, S. and Tielsen, I., Diphenylhydantoin: A comparative study on normal cats and animals intoxicated with digitalis glycosides, Basic Research in Cardiology, 69: 289-308, 1974.

964. Dill, R. E., Adrenal cortical response in rats treated with diphenylhydantoin sodium, Anat. Rec., 148: 366, 1964.

965. Dill, W. A., Baukema, J., Chang, T., and Glazko, A. J., Colorimetric assay of 5,5-diphenylhydantoin (Dilantin) and 5 (p hydroxyphenyl) 5 phenylhydantoin, Epilepsy Abstracts, 4: 262, 1971.

966. Dill, W. A., Chucot, L., Chang, T., and Glazko, A. Simplified benzophenone procedure for determination of diphenylhydantoin in plasma, Clin. Chem., 17: 1200-1201, 197 1.

967. Dilman, V. M., Elivbaeva, G. V., Vishnevskii, A. S., Tsyrilina, E. V., and Bulovskaia, L. N., Justification of the use of diphenine (diphenylhydantoin) in oncologic practice, Vop. Onkol., 17: 70-72, 1971.

968. Doe, W. F., Hoffbrand, A. V., Reed, P. I., and Scott, J. M., jejunal pH and folic acid, Brit. Med. J., 699-700, 197 1.

969. Doherty, 1. E., Digitalis glycosides. Pharmacokinetics and their clinical implications, Ann. Intem. Med., 79: 229-238, 1973.

970. Domino, E. F. and Olds, M. E., Effects of d-amphetamine, scopolamine, chlor-diazepoxide and diphenylhydantoin on self-stimulation behavior and brain acetylcholine, Psychopharmacologia (Berlin), 23: 1-16, 1972.

971. Domzal, T., Effect of diphenylhydantoin on clinical manifestations and excretion of 5-hydroxyindoleacetic acid in Parkinson’s disease, Neurol. Neurochir. Pol., 6: 357-360, 1972.

972. Dreifus, L. S. and Watanabe, Y., Current status of diphenylhydantoin, Amer. Heartj., 80: 709-713, 1970.

973. Dreifus, L. S., de Azevedo, 1. M., and Watanabe, Y., Electrolyte and antiarrhythmic drug interaction, Amer. Heart J., 88: 95-107, 1974.

974. Dreifus, L. S., Management of intractable atrial arrhythmias, Mechanisms and Therapy of Cardiac Arrhythmias, 205-210, Dreifus, L. S. and Ukoff, W., Eds., Grune and Stratton, New York,1966.

975. Dreifus, L. S., Use of quinidine, procainamide and diphenythydantoin, Cardiovascular Therapy, The Art and The Science, 109-112, Russek, H. 1. and Zohman, B. L., Eds., The Williams & Wilkins Co., Baltimore, 197 1.

976. Dreifuss, F. E. and Sato, S., Anticonvulsant drugs in clinical practice, Drug Therapy, 2: 9-22, 1972.

977. Dreifuss, F. E., Diphenylhydantoin and visceral atony, Drug Therapy, 3: 101-102,1973.

978. Dressier, W. E., Rossi, G. V., and Orzechowski, R. F., Effect of several anticonvulsant drugs and procainamide against ouabain-induced cardiac arrhythmias in rabbits, J. Pharm. Sci., 61: 133-134, 1972.

979. Driessen, 0. and Ernonds, A., Simultaneous determination of antiepdeptic drugs in small samples of blood plasma by gas chromatography. Column technology and extraction procedure. Epilepsy Abstracts, 7: 203-204, 1974.

980. Dronamraju, K. R., Epilepsy and cleft lip and palate, Lancet, 876-877, 1970.

981. Dry, J. and Pradalier, A., Phenytoin intoxication during treatment combined with disulfiram, Therapie, 28: 799-802.1973.

982. Ducker, T. B., Blaylock, R. L. D., and Perot, P. L., Jr., Emergency care of patients with cerebral injuries, Postgrad. Med., 55: 102-110, 1974.

983. Dudley, W. H. C., Jr., and Williams, J. G., Electroconvulsive therapy in delirium tremens, Dig. Neurol. Psychiat., Series XL: 333,1972.

984. Dujovne, C. A., Clark, R., and Lasagna, L., Calcium and CNS symptoms, New Eng. J. Med., 281: 271-272, July, 1969.

985. Eadie, M. I., Tyrer, J. H., and Hooper, W. D., Aspects of diphenylhydantoin metabolism, Proc. Aust. Assoc. Neurol., 7: 7-13, 1970.

986. Eastham, R. D. and Jancar, J., Macrocytosis associated with anticonvulsant therapy, Epilepsia, 11: 275-280, 1970.

987. Eddy, J. D. and Singh, S. P., Treatment of cardiac arrhythmias with phenytoin, Brit. Mod. J., 4: 270-273, 1969.

988. Editor, A guide to selection of a systemic antibacterial agent, Drugs, 4: 132-145, 1972.

989. Editor, Anticonvulsant drugs and hypocalcaemia, Brit. Med. J., 4: 351, 1973.

990. Editor, Anticonvulsants or antiepileptics, Behavioral Neuropsychiatry, 3: 14-16, 197 1.

991, Editor, Diphenylhydantoin for digitalis toxicity, Postgrad. Med., 45: 244-245, 1969.

992. Editor, For tic douloureux, lasting relief, Medical World News, 14: 66-67, 1973.,

993. Editor, Monitoring drug therapy, Lancet, 668, 1974.

994. Editor, Phenytoin and carbamazepine combined, Brit. Med. J., 1: 113, 1974.

995. Editor, Some important interactions with anticonvulsant drugs, J. International Res. Communication, 2: 5-7, 1974.

996. Editor, Treatment of trigeminal neuralgia, Brit. Med. 2: 583-584, 1972.

997. Editors, Panel discussion: hormones and fetal metabolisrn, Clin. Pharmacol. Ther., 14: 742-747, 1973.

998. Edmundson, W. F., Davies, J. E., Maceo, A., and Morgade, C., Drug and environmental effects on DDT residues in human blood, Southern Med. J., 63: 1440-1441, 1970.

999. Edmundson, W. F., Frazier, D. E., and Maceo, A., Sequential biochemical tests in persons taking pH phenytoin, Indust. Med., 41: 7-11, 1972.

1000. Ehrnebo, M., Agurell, S.,Jalling, B., and Boreus, L. O., Age differences in drug binding by plasma proteins: studies on human fetuses, neonates and adults, Europ. J. Clin. Pharmacol., 3: 189-193, 1971.

1001. Eipe, J., Drugs affecting therapy with anticoagulants, Med. Clin. N. Amer., 56: 255-262, 1972.

1002. Eisen, A. A., Woods, J. F., and Sherwin, A. L., Peripheral nerve function in long-term therapy with diphenylhydantoin, Neurology, 24: 411-417, 1974.

1003. Eling, T. E., Harbison, R. D., Becker, B. A., and Fouts, J. R., Diphenylhydantoin effect on neonatal and adult rat hepatic drug metabolism, J. Pharmacol. Exp. Ther., 171: 127-134, 1970.

1004. Eling, T. E., Harbison, R. D., Becker, B. A., and Fouts, J. R., Kinetic changes in microsomal drug metabolism with age and diphenylhydantoin treatment, Europ. J. Pharmacol., 11: 101-108, 1970.

1005. Ellenberger, C., Burde, R. M., and Keltner, J. L., Acute optic neuropathy, Arch. Ophthal., 91: 435-438, 1974.

1006. Elliott, T. H. and Natarajan, P. N., Infrared studies of hydantoin and its derivatives, J. Pharm. Pharmacol., 19: 209-216, 1966.

1007. Ellis, J. G. and Dimond, E. G., Newer concepts of digitalis, Amer. J. Cardiol., 17: 759-767, 1966.

1008. Eishove, J. and Van Eck, J. H. M., Congenital malformations, cleft lip and palate in particular, in children of epileptic women, Ned. T.3dschr. Geneesk., 115: 1371-1375, 1971. (cf. Elshove, Lancet, 1074, 1969.)

1009. Elwood,j. C., Richert, D. A., and Westerfeld, W. W., A comparison of hypolipidemic drugs in the prevention of an orotic acid fatty liver, Biochem. Pharmacol., 21: 1127-1134,1972.

1010. Erdey, L., Kaplar, L., Takacs, J. and Dessouky, Y. M., Determination of hydantoins in pharmaceutical preparations by gas chromatography, J. Chromatogr., 45: 63-67, 1969.

1011. Erickson, J. D. and Oakley, G. P., Seizure disorder in mothers of children with orofacial clefts: a case control study, J. Pediat., 84: 244-246, 1974.

1012. Escueta, A. V. and Appel, S. H., Brain synapses-an in vitro model for the study of seizures, Arch. Intern. Med., 129: 333-344, 1972.

1013. Escueta, A. V. and Appel, S. H., The effects of ellectroshock seizures on potassium transport within synaptosomes from rat brain, Epilepsy Abstracts, 5: 205, 1972.

1014. Escueta, A. V. and Appel, S. H., Diphenylhydantoin and potassium transport in isolated nerve terminals, J. Clin. Invest., 50: 1977-1984, 197 1.

1015. Esposito-Avelia, M. and Mennear, J. H., Studies on the protective effect of diphenylhydantoin against alloxan diabetes in mice, Proc. Soc. Exp. Biol. Med., 142: 82-85,1973.

1016. Evans, D. E. and Gillis, R. A., Effect of diphenylhydantoin (DPH) on centrally induced vagal arrhythmias, Pharmacologist, 13: Abstract 188, 197 1.

1017. Evenson, M. A.,Jones, P., and Darcey, B., Simultaneous measurement of diphenylhydantoin and primidone in serum by gas-liquid chromatography, Clin. Chem., 16: 107-110, 11370.

1018. Fariss, B. L. and Lutcher, C. L., Diphenylhydantoin induced hyperglycemia and impaired insulin release-effect of dosage, Diabetes, 20: 177-181, 1971 .

1019. FDA, Anticonvulsant linked with birth defect risk, FDA Drug Bulletin, July, 1974.

1020. Fedrick, J., Epilepsy and pregnancy: a report from the Oxford record linkage study, Brit. Med. J., 2: 442-448, 1973.

1021. Ferrari,M.and Furianut, M.,Effects of diphenylhydantoin on smooth muscle, Arch. Int. Pharmacodyn., 203: 101-106, 1973.

1022. Ferry, D. G., Owen, D., and McQueen, E. G., The effect of phenytoin on the binding of pesticides to serum proteins, Proc. Univ. Otago Med. School, 50: 8-9, 1972.

1023. Fertziger, A. P. and Dunham, P. B., Diphenylhydantoin stimulation of potassium influx in isolated lobster axons, Epilepsy Abstracts, 5: 61, 1972.

1024. Fertziger, A. P., Brain extracellular space: some considerations on the role it plays in brain function, Cond. Reflex, 8: 224-232, 1973.

1025. Fertziger, A. P., Liuzzi, S. E., and Dunham, P. B., Diphenylhydantoin (Dilantin): stimulation of potassium influx in lobster axons, Brain Res., 33: 592-596, 1971.

1026. Fertziger, A. P., Lynch, J. J., and Stein, E. A., Modification of the morphine withdrawal syndrome in rats, Brain Res., 78:331-334, 1974.

1027. Fertziger, A. P., Stein, E. A., and Lynch, J. J., Suppression of morphine-induced mania in cats, Psychopharmacologia, 36: 185-187, 1974.

1028. Festoff, B. W. and Appel, S. H., The effect of diphenylhydantoin on synaptosome metabolism, Neurology, 19: 300, 1969.

1029. Fica, V., Panaitescu, G., Matrescu, F., and Popescu, E.. indications and limitations of anti-arrhythmic drugs, Med. Intern., 23: 523-536,1971.

1030. Fincham, R. W., Schottelius, D. D., and Sahs, A. L., The influence of diphenylhydantoin on primidone metabolism, Arch. Neurol., 30: 259-262, 1974.

1031. Finkle, B. S., Foltz, R. L., and Taylor, D. M., A comprehensive GC-MS reference data system for toxiciological and biomedical purposes, J. Chromatogr. Sci., 12: 304-328, 1974.

1032. Fish, B., The “one child, one drug” myth of stimulants in hyperkinesis, Arch. Gen. Psychiat., 25: 193-203, 197 1.

1033. Fisher, D. and DiMino, J. M., Case presentation of an alternative therapeutic approach for the borderline psychotic heroin addict: diphenylhydantoin, Br. J. Addict., 70: 51-55, 1975.

1034. Fisher, D. D. and Ungerleider, J. T., Grand mal seizures following ingestion of  LSD, Calif. Mod., 106: 210-211, 1967.

1035. Formby, B., The in vivo and in vitro effect of diphenylhydantoin and phenobarbitone on K’-activated phosphohydrolase and (NA+,K+)-activated ATPase in particulate membrane fractions from rat brain, J. Pharm. Pharmacol., 22: 81-85, 1970.

1036. Fouts, J. R. and Kurt, H., Diphenylhydantoin, some studies on the biotransformation and interactions with some other drugs and chemicals, Antiepileptic Drugs, 163-168, Woodbury, D. M., Penry, J. K., and Schmidt, R. P., Eds., Raven Press, New York, 1972.

1037. Freiwaid, M. J., Prevention of complications of Herpes Zoster ophthalmicus with special reference to steroid therapy, Eye, Ear, Nose and Throat Monthly, 46: 444-450, 1967.

1038. Frenkel, E. P., McCall, M. S. and Sheehan, R. G., Cerebrospinal fluid folate, and vitamin B12 in anticonvulsant-induced megaloblastosis, J. Lab. Clin. Med., 81: 105-115, 1973.

1039. Friedlander, W. J., Epilepsy1973, The Clinical Neurology Information Center, The University of Nebraska Medical Center, 1-45, 1974.

1040. Friedman, A. P., An overview of chronic recurring headache, Wisconsin Med. J., 71: 110-116, 1972.

Advisory